<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12133506</article-id><article-id pub-id-type="pmcid-ver">PMC12133506.1</article-id><article-id pub-id-type="pmcaid">12133506</article-id><article-id pub-id-type="pmcaiid">12133506</article-id><article-id pub-id-type="pmid">40469313</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1567584</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Peptide vaccines: an innovative therapeutic approach against antibiotic-resistant bacterial infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tavassoli Razavi</surname><given-names initials="F">Fatemeh</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3064902/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salari</surname><given-names initials="N">Nasrin</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Emami</surname><given-names initials="A">Atena</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haghmorad</surname><given-names initials="D">Dariush</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/395857/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Baharlou</surname><given-names initials="R">Rasoul</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2959830/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Department of Immunology, School of Medicine, Semnan University of Medical Sciences</institution>, <addr-line>Semnan</addr-line>, <country>Iran</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Xingmin Sun, University of South Florida, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Hasanain Odhar, Al-Zahrawi University College, Iraq</p><p>Neelam Sharma, B V Raju Institute of Technology, India</p></fn><corresp id="fn001">*Correspondence: Rasoul Baharlou, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:baharlour@gmail.com">baharlour@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480569</issue-id><elocation-id>1567584</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-05 11:25:42.047"><day>05</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Tavassoli Razavi, Salari, Emami, Haghmorad and Baharlou</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tavassoli Razavi, Salari, Emami, Haghmorad and Baharlou</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-16-1567584.pdf"/><abstract><p>Bacterial infections continue to pose a serious threat to global health, especially with the growing challenge of multidrug-resistant pathogens. While traditional vaccines have been pivotal in reducing disease burden, they come with limitations such as variable efficacy, safety concerns, and limited ability to address the diversity of bacterial strains. This review highlights the promise of peptide-based vaccines as an innovative approach to overcoming these hurdles. By targeting specific regions of bacterial proteins, peptide vaccines can elicit precise immune responses with improved safety and broader applicability. Advances in technology, including bioinformatics and delivery systems, have enhanced their design, making them more stable, effective, and easier to produce. These vaccines work by activating both antibody and T-cell responses through well-defined mechanisms. Different types, such as linear peptides, cyclic peptides, and synthetic long peptides, offer diverse strategies to tailor immune protection. The role of adjuvants and advanced delivery methods, like nanoparticles and liposomes, further improve their potential. Exciting progress has been made against the ESKAPE pathogens &#8212; <italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Enterobacter</italic> spp. Peptide vaccines offer a forward-thinking, adaptable solution to reduce bacterial infections and mitigate the rise of antibiotic resistance, paving the way for safer and more effective prevention strategies. This review underscores the critical role of peptide-based vaccines in combating bacterial infections, advocating for ongoing research to unlock their full potential.</p></abstract><kwd-group><kwd>peptide vaccines</kwd><kwd><italic toggle="yes">Enterococcus faecium</italic></kwd><kwd>methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></kwd><kwd><italic toggle="yes">Klebsiella pneumoniae</italic></kwd><kwd><italic toggle="yes">Acinetobacter baumannii</italic></kwd><kwd><italic toggle="yes">Pseudomonas aeruginosa</italic></kwd><kwd><italic toggle="yes">Enterobacter</italic> spp</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="126"/><page-count count="14"/><word-count count="5970"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Vaccines and Molecular Therapeutics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Bacterial infections remain a major global health problem, causing substantial morbidity and mortality; notably in low-&#8194;and middle-income countries (LMICs) with challenging healthcare system resources (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Tens of millions die from bacterial diseases, including respiratory infections caused by tuberculosis and pneumonia (<xref rid="B3" ref-type="bibr">3</xref>). These infections predominantly affect young children, elder people and people with compromised immune systems (<xref rid="B4" ref-type="bibr">4</xref>). Among the top five global causes of death are lower respiratory tract infections (LRTIs); pneumonia is the most common (<xref rid="B5" ref-type="bibr">5</xref>). Along with pneumonia, other bacterial infections&#8212;such as bloodstream infections (sepsis), urinary tract infections (especially catheter-associated), and bacterial meningitis&#8212;contribute significantly to global mortality, particularly when caused by multidrug-resistant organisms (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Vaccination remains one of the most effective public health interventions to prevent bacterial infections. Vaccines prime the immune system, enabling it to recognize and respond to pathogens before an infection can be established (<xref rid="B7" ref-type="bibr">7</xref>). Conventional vaccines &#8212; live-attenuated, inactivated, and subunit vaccines &#8212; have significantly decreased the incidence of various bacterial diseases. However, these approaches have intrinsic limitations. For instance, although live-attenuated vaccines are highly immunogenic, they pose safety concerns since the attenuated strains can revert to a virulent form, particularly in the immunocompromised host (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B10" ref-type="bibr">10</xref>). Inactivated vaccines are safer but they often trigger only moderate immune responses, requiring the use of adjuvants or booster doses (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Subunit vaccines, which employ purified pathogen components, frequently fail to generate durable immunity (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Additionally, the diversity of bacterial antigens is a major problem. Traditional vaccines are often strain- or serotype-specific, limiting their broad use (<xref rid="B12" ref-type="bibr">12</xref>).</p><p>The increase in multidrug-resistant (MDR) bacteria highlights the need for new vaccines. Antibiotic resistance has reached a global crisis, with MDR pathogens such as methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) and <italic toggle="yes">carbapenem-resistant Enterobacteriaceae</italic>, emerging as major public health threats (<xref rid="B13" ref-type="bibr">13</xref>). These so-called &#8220;superbugs&#8221; (<xref rid="B14" ref-type="bibr">14</xref>) are particularly alarming as they cause hard-to-treat infections, leading to increased morbidity, mortality, and healthcare costs (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>In addition to their resistance to antibiotics, MDR bacteria have evolved multiple immune evasion strategies that enable persistence and pathogenicity (<xref rid="B16" ref-type="bibr">16</xref>). These include biofilm formation, which creates a physical barrier that impedes phagocytosis and limits immune cell access (<xref rid="B17" ref-type="bibr">17</xref>); secretion of immunomodulatory toxins, such as leukocidins and hemolysins, which damage immune cells or disrupt cytokine signaling (<xref rid="B18" ref-type="bibr">18</xref>); antigenic variation, involving changes in surface antigens that help bacteria escape recognition by antibodies and T-cells (<xref rid="B19" ref-type="bibr">19</xref>); inhibition of phagocytosis, via surface proteins (e.g., protein A in <italic toggle="yes">S. aureus</italic>) that bind antibodies in a non-opsonizing orientation (<xref rid="B20" ref-type="bibr">20</xref>); and downregulation of antigen presentation, where bacterial factors interfere with major histocompatibility complex (MHC)" expression, limiting T-cell activation (<xref rid="B21" ref-type="bibr">21</xref>). These sophisticated strategies enable pathogens to evade both innate and adaptive immunity, establish chronic infections, and challenge vaccine-mediated protection. Consequently, there is an imperative to develop innovative vaccine platforms that not only prevent infection but also reduce antibiotic reliance and effectively counter bacterial immune evasion strategies.</p><p>The bacterial peptide-based vaccine is a new paradigm of bacterial&#8194;immunization that uses short sequences of amino acids from pathogen-specific antigens to elicit a targeted response against specific epitopes (the portions of antigens that the immune system uses to recognize pathogens). Peptide vaccines bypass risks associated with using whole pathogens,&#8194;such as reversion to virulence, associated with traditional approaches. Peptide vaccines targeting conserved protein regions critical to bacterial survival and less prone to mutation offer the possibility of broad immunity and can effectively combat antigenic variation (<xref rid="B22" ref-type="bibr">22</xref>). New insights from bioinformatics and proteomics have played a major role in discovering immunogenic peptides. This allows the rational design of vaccines against individual pathogens or multiple strains (<xref rid="B23" ref-type="bibr">23</xref>). In addition to providing immunological advantages, peptide vaccines offer significant logistical and economic benefits. Their synthetic derivation makes them easy to manufacture, which lowers production costs and simplifies storage and distribution (<xref rid="B10" ref-type="bibr">10</xref>). Innovative delivery systems, such as nanoparticle-based carriers, enhance peptide stability and facilitate targeted endocytic uptake by antigen-presenting cells. This promotes efficient processing and presentation of epitopes on MHC class I and II molecules, thereby eliciting robust humoral and cellular immune responses and optimizing overall vaccine immunogenicity and efficacy (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>).</p><p>In general, peptide-based vaccines present a promising, flexible approach to overcoming many of the challenges faced by traditional bacterial vaccines. Offering a targeted, customizable, and potentially safer solution, they have the potential to significantly reduce the global impact of bacterial infections, especially as antibiotic resistance continues to rise. Continued research into peptide immunization is essential to harness their full potential in creating effective, lasting vaccines against a wide range of bacterial pathogens. In this review, we examined the benefits and future approaches of peptide vaccines.</p></sec><sec id="s2"><label>2</label><title>Mechanisms of peptide vaccines in immunity against bacterial infections</title><sec id="s2_1"><label>2.1</label><title>Immunological basis of peptide vaccines</title><p>Peptide vaccines offer several advantages, including precise antigen targeting, favorable safety profiles, and the ability to induce both humoral and cellular immune responses (<xref rid="B22" ref-type="bibr">22</xref>). The fundamental mechanism underlying their immunogenicity involves the presentation of antigenic peptides by MHC molecules to T-cells, thereby initiating an adaptive immune response against bacterial pathogens (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>) (<xref rid="B26" ref-type="bibr">26</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Schematic illustration of the immune response to a peptide vaccine. Upon injection of the vaccine, microbial peptides are internalized by dendritic cells, which then process and present them via MHC class II <bold>(A)</bold> and I <bold>(B)</bold> molecules to CD<sub>4</sub>
<sup>+</sup> and CD<sub>8</sub>
<sup>+</sup> T-cells. This interaction leads to the secretion of IL-2 and TNF-&#945; by DC on CD<sub>4</sub>
<sup>+</sup> T-cells <bold>(A)</bold>. Activated CD<sub>4</sub>
<sup>+</sup> T-cells enhance CD<sub>8</sub>
<sup>+</sup> T-cells function by secreting IFN-&#947; and IL-2, which promote bacterial killing through perforin and granzyme release <bold>(A1)</bold>. Additionally, CD<sub>4</sub>
<sup>+</sup> T-cells stimulate B-cells to differentiate into plasma cells to produce antibodies <bold>(A2)</bold>, and also activate macrophages to recognize and phagocytose antibody-opsonized bacteria <bold>(A3)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1567584-g001.jpg"/></fig><sec id="s2_1_1"><label>2.1.1</label><title>Antigen presentation by MHC molecules and T-cell activation</title><p>These studies generally design peptide vaccines that are composed of selected amino acid sequences, termed epitopes, which correspond to the immunogenic regions of bacterial antigens. Following administration, such epitopes are internalized by antigen-presenting cells, mainly dendritic cells (<xref rid="B27" ref-type="bibr">27</xref>). The cell processes the peptides and then presents them on the surface in association with MHC molecules. MHC class I and II present peptides to cytotoxic CD<sub>8</sub>
<sup>+</sup> T and CD<sub>4</sub>
<sup>+</sup>T helper cells, which play a crucial role in coordinating the immune response through the elimination of intracellular pathogens and secretion of cytokines that support both cellular and humoral immunity (<xref rid="B28" ref-type="bibr">28</xref>). Dendritic cells, along with the presentation of peptides with MHC class II, secrete interleukin 2 and TNF-&#945; on CD<sub>4</sub>
<sup>+</sup>T to activate it (<xref rid="B29" ref-type="bibr">29</xref>). The efficacy of peptide vaccines is strongly influenced by the ability of the epitopes to bind to MHC molecules, which promotes T-cell activation and a potent immune defense against bacterial infections.</p></sec><sec id="s2_1_2"><label>2.1.2</label><title>Stimulation of humoral and cellular immune responses</title><p>A well-designed vaccine should trigger both humoral and cellular immune responses to provide comprehensive protection against bacterial pathogens. Activated CD<sub>4</sub>
<sup>+</sup>T activates B-cells by secreting INF-&#947; and interleukins such as 4 and 5. The humoral immune response, driven by B-cell activation and antibody production, is essential for neutralizing extracellular bacteria and preventing colonization. The antibodies can neutralize bacterial toxins, inhibit bacterial adhesion to host tissues, and facilitate opsonization, marking bacteria for phagocytosis (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Cellular immunity, primarily mediated by T-cells, plays a crucial role in the defense against intracellular pathogens. Cytotoxic CD<sub>8</sub>
<sup>+</sup> T-cells recognize and eliminate infected cells, and CD<sub>4</sub>
<sup>+</sup> helper T-cells stimulate phagocytic activity and also enhance the responses of cytotoxic T-cells by secreting INF-&#947; and interleukin 2, contributing to the development of lasting immunity (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Peptide vaccines aim to induce a comprehensive and durable immune response against bacterial infections by targeting epitopes that engage both humoral and cellular immunity.</p></sec></sec><sec id="s2_2"><label>2.2</label><title>Types of peptide vaccines</title><p>Peptide vaccines are classified based on the structure of the peptide as well as its targeted immune response. There are a few categories of peptides, such as linear peptides, cyclic peptides, epitope-based peptides, and synthetic long peptides&#8194;(SLPs). Different types have distinct advantages for bacterial vaccine development.</p><sec id="s2_2_1"><label>2.2.1</label><title>Linear vs. cyclic peptides</title><p>Most peptide vaccines are based on linear epitopes&#8212;short, sequential amino acid fragments derived from pathogenic proteins. These are relatively easy to identify, synthesize, and screen using high-throughput platforms. However, linear peptides often fail to replicate the native three-dimensional structure of proteins, leading to reduced stability and suboptimal immune recognition <italic toggle="yes">in vivo</italic>. In contrast, conformational epitopes&#8212;formed by amino acid residues brought together by protein folding&#8212;are typically more immunogenic as they better resemble the native surface of pathogens recognized by B-cell receptors. Peptide vaccines face a fundamental limitation in effectively presenting these conformational structures due to the inherent flexibility and lack of structural complexity of linear peptides. Cyclic peptides, by forming stable and rigid ring structures, can mimic conformational epitopes more accurately. Their restricted conformational mobility enhances binding specificity to MHC molecules and immune receptors, and increases resistance to enzymatic degradation. Thus, employing cyclic peptides in vaccine design can partially overcome the challenge of inducing immune responses against conformational epitopes, though reproducing full protein structures remains difficult in synthetic constructs (<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>).</p></sec><sec id="s2_2_2"><label>2.2.2</label><title>Epitope-based peptides</title><p>Epitope-based vaccines are composed of peptides representing either T-cell or B-cell epitopes. T-cell epitopes are selected based on their ability to bind MHC molecules, leading to the activation of cytotoxic T lymphocyte (CTL) or helper T-cell responses that are essential for combating intracellular pathogens. In contrast, B-cell epitopes&#8212;often derived from surface-exposed regions of bacterial proteins&#8212;aim to induce robust antibody responses, which are critical for neutralizing extracellular pathogens (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). To enhance immunogenic breadth, multiple epitopes can be combined into a single construct, resulting in multiepitope-based peptide vaccines (<xref rid="B36" ref-type="bibr">36</xref>). These constructs are designed through a rational, immunoinformatics-driven process involving the prediction and selection of highly antigenic, non-toxic, and non-allergenic epitopes with broad population coverage. Then, the selected epitopes are assembled using appropriate peptide linkers and, in some cases, fused to molecular adjuvants or carrier sequences to enhance immunogenicity (<xref rid="B37" ref-type="bibr">37</xref>). The choice of linker is critical for maintaining proper antigen processing and structural integrity. Flexible linkers such as AAY or KK are often used to join CTL and B-cell epitopes due to their capacity to promote proteasomal cleavage and enhance epitope presentation. However, their high conformational mobility may result in reduced structural integrity, unwanted interactions between adjacent epitopes, or impaired biological activity. On the other hand, rigid linkers like EAAAK provide fixed spatial separation between functional domains, helping to maintain proper folding and minimize domain interference but may hinder the conformational flexibility needed for antigen processing by APCs. Thus to ensure optimal structural conformation and antigen processing, peptide linkers are chosen based on the structural and immunological demands of the vaccine construct (<xref rid="B37" ref-type="bibr">37</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>). Following design, the synthetic gene encoding the multi-epitope construct is codon-optimized and recombinantly expressed in suitable host systems. The suitability of these vaccine candidates depends on several critical parameters, including physicochemical stability, expression yield, proper folding, epitope accessibility, and cost-effectiveness of production. (<xref rid="B37" ref-type="bibr">37</xref>). Multiepitope vaccines have demonstrated promise against antigenically diverse or drug-resistant pathogens&#8212;such as ESKAPE bacteria&#8212;by eliciting multi-faceted immune responses and potential cross-protection.</p></sec><sec id="s2_2_3"><label>2.2.3</label><title>Synthetic long peptides</title><p>SLPs are longer peptides, 20 to 35 amino acids long, that contain multiple T-and B-cell epitopes within a single structure. This enables the activation of both arms of the immune system. SLPs often have multiple MHC-binding sites, enabling a broader T-cell response and increased potential for cross-reactivity. Their design imitates natural antigens in a way that enhances antigen presentation and immune recognition. These features make SLPs promising for inducing strong and lasting immunity in bacterial vaccine development (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>).</p></sec></sec><sec id="s2_3"><label>2.3</label><title>Adjuvants and delivery systems</title><p>To enhance the immunogenicity of peptide vaccines, adjuvants and advanced delivery systems are often used. Adjuvants amplify the immune response to an antigen, while delivery systems control the release of the vaccine and target its delivery, overcoming the low immunogenicity of isolated peptide antigens (<xref rid="B42" ref-type="bibr">42</xref>).</p><sec id="s2_3_1"><label>2.3.1</label><title>Adjuvants in enhancing immunogenicity</title><p>Adjuvants stimulate immune cells and prolong antigen exposure, thereby enhancing vaccine efficacy. Traditional adjuvants, such as alum, play a major role in promoting antibody responses. However, newer adjuvants, including Toll-like receptor (TLR) agonists, saponins, and liposomes, are designed to boost cellular immunity by activating dendritic cells and promoting antigen presentation. In peptide vaccines, adjuvants are particularly valuable as they provide &#8220;danger signals&#8221; that amplify the immune response (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Despite their efficacy, the use of adjuvants comes with potential risks, particularly concerning their safety. Overuse or inappropriate selection of adjuvants can result in allergic reactions and, in some cases, autoimmune disorders. For example, TLR agonists may overstimulate the immune system, leading to unwanted inflammatory responses or hypersensitivity, especially in vulnerable individuals. Additionally, some adjuvants, such as saponins, have been linked to local reactions and systemic toxicity. These risks necessitate careful optimization and controlled usage of adjuvants in peptide vaccines to prevent any adverse effects (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p></sec><sec id="s2_3_2"><label>2.3.2</label><title>Delivery systems: nanocarriers, liposomes, and conjugate vaccines</title><p>New delivery systems, including nanocarriers and liposomes, have been developed that protect peptides from degradation, control their release rate, and target the immune cells with high precision. Nanocarriers, consisting of nanoparticles and polymer systems, can encapsulate peptides for protection and assured delivery to the APCs. Nanoparticles may be prepared as pathogen imitations that can be taken up by dendritic cells at enhanced rates, therefore promoting antigen presentation (<xref rid="B46" ref-type="bibr">46</xref>). Since liposomes are vesicular carriers of lipids, they would, in turn, encapsulate the peptides for longer circulation and specific delivery to immune cells. They also act as an adjuvant and enhance humoral and cellular responses (<xref rid="B47" ref-type="bibr">47</xref>). Conjugate vaccines link peptides to carrier proteins such as tetanus or diphtheria toxoids. They enhance immunogenicity by providing extra T-cell epitopes. This approach is quite useful in groups where immune responses are generally poor, such as older adults and young children (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>Despite their advantages, each delivery modality carries specific safety concerns. Nanocarriers may induce dose&#8722;dependent cytotoxicity, oxidative stress, and pro&#8722;inflammatory cytokine release&#8212;effects that vary with particle size, surface charge, and composition, and can lead to tissue damage or systemic inflammation (<xref rid="B49" ref-type="bibr">49</xref>). Liposomes are prone to complement activation&#8722;related pseudo-allergy (CARPA), manifesting as infusion&#8722;related hypersensitivity (flushing, dyspnea, hypotension) in susceptible individuals (<xref rid="B50" ref-type="bibr">50</xref>). Conjugate vaccines, while generally well tolerated, can cause local injection&#8722;site reactions and, in rare cases, carrier&#8722;induced epitope suppression, whereby pre&#8722;existing immunity to the protein carrier (e.g., tetanus toxoid) diminishes the response to the linked peptide antigen (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>).</p></sec></sec></sec><sec id="s3"><label>3</label><title>Peptide vaccines against bacterial infections</title><p>As mentioned, peptide vaccines have emerged as a therapeutic strategy by targeting specific antigenic determinants, which can induce precise and potent immune responses against a wide range of bacterial pathogens in the fight against bacterial infections. One of the most promising strategies in this context involves the use of conserved regions of bacterial proteins. These conserved sequences are shared across multiple strains or species of a pathogen and are less prone to mutation, making them ideal targets for vaccine development. Targeting such regions ensures broader coverage against diverse bacterial variants, including multidrug-resistant strains. Furthermore, these proteins are predicted to be highly antigenic and essential for pathogen survival and reduces the risk of immune escape due to antigenic variation. Moreover, peptides derived from conserved epitopes are more likely to elicit cross-protective immune responses, which is crucial for combating the genetic variability characteristic of ESKAPE pathogens (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p><p>This review analyzes the development of peptide vaccines for the ESKAPE pathogens &#8212; <italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Enterobacter</italic> spp. &#8212; each of which presents unique challenges in immunogenicity and pathogen persistence. Peptide vaccines in development against ESKAPE are shown in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Peptide vaccines in development against ESKAPE.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Bacterium</th><th valign="middle" align="center" rowspan="1" colspan="1">Target(s) of Peptide Vaccine</th><th valign="middle" align="center" rowspan="1" colspan="1">Development Stage</th><th valign="middle" align="center" rowspan="1" colspan="1">Source(s)</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">PspA, PhtD<break/>PspA, PhtD, PspC<break/>PspA, CbpA, PhtD, PiuA</td><td valign="top" align="center" rowspan="1" colspan="1">Preclinical<break/>Preclinical<break/>Preclinical</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B55" ref-type="bibr">55</xref>)<break/>(<xref rid="B56" ref-type="bibr">56</xref>)<break/>(<xref rid="B57" ref-type="bibr">57</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">PspC</td><td valign="top" align="center" rowspan="1" colspan="1">In silico</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">PhtD, PcpA<break/>PcpA, PhtD, PlyD1<break/>dPly, PhtD</td><td valign="top" align="center" rowspan="1" colspan="1">Clinical trials - Phase I<break/>Clinical trials - Phase I<break/>Clinical trials - Phase I &amp; II</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B59" ref-type="bibr">59</xref>)<break/>(<xref rid="B60" ref-type="bibr">60</xref>)<break/>(<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">ClfA, ClfB<break/>R13</td><td valign="top" align="center" rowspan="1" colspan="1">Preclinical<break/>Preclinical</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B63" ref-type="bibr">63</xref>)<break/>(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">MABC, NABC, and PIc</td><td valign="top" align="center" rowspan="1" colspan="1">Preclinical</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B65" ref-type="bibr">65</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">Alpha-enolase, ClfA, IsdB<break/>FnBPA, FnBPB<break/>Glycosyltransferase, EBP, Staphylococcal secretory antigen</td><td valign="top" align="center" rowspan="1" colspan="1">In silico<break/>In silico<break/>In silico</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B66" ref-type="bibr">66</xref>)<break/>(<xref rid="B67" ref-type="bibr">67</xref>)<break/>(<xref rid="B68" ref-type="bibr">68</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">ClfB, FnbpA, Hla, IsdA, IsdB, LukE, SdrD, and SdrE</td><td valign="top" align="center" rowspan="1" colspan="1">In silico &amp; Preclinical</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">rFSAV<break/>IsdB</td><td valign="top" align="center" rowspan="1" colspan="1">Clinical trial - Phase II<break/>Clinical trial - Phase II</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B70" ref-type="bibr">70</xref>)<break/>(<xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">OprF, OprI</td><td valign="top" align="center" rowspan="1" colspan="1">Clinical trials - Phase II &amp; III<break/>Clinical trials - Phase II<break/>Clinical trials - Phase I</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B72" ref-type="bibr">72</xref>)<break/>(<xref rid="B73" ref-type="bibr">73</xref>)<break/>(<xref rid="B74" ref-type="bibr">74</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">PilA<break/>PBD</td><td valign="middle" align="center" rowspan="1" colspan="1">Preclinical<break/>Preclinical</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B75" ref-type="bibr">75</xref>)<break/>(<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">OprF, OprE<break/>fructose bisphosphate aldolase (FBA)</td><td valign="top" align="center" rowspan="1" colspan="1">In silico<break/>In silico</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B77" ref-type="bibr">77</xref>)<break/>(<xref rid="B78" ref-type="bibr">78</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcus faecium</italic> (VRE)</td><td valign="top" align="center" rowspan="1" colspan="1">PBP5<break/>Psts</td><td valign="top" align="center" rowspan="1" colspan="1">In silico<break/>In silico</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)<break/>(<xref rid="B80" ref-type="bibr">80</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic> (CRKP)</td><td valign="top" align="center" rowspan="1" colspan="1">OmpA, OmpW, and FepA (mHla-EpiVac)<break/>P40</td><td valign="top" align="center" rowspan="1" colspan="1">Preclinical<break/>Preclinical</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>)<break/>(<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic> (CRKP)</td><td valign="top" align="center" rowspan="1" colspan="1">type 3 fimbrial protein<break/>OMPK17<break/>FepA</td><td valign="top" align="center" rowspan="1" colspan="1">In silico<break/>In silico<break/>In silico</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B83" ref-type="bibr">83</xref>)<break/>(<xref rid="B84" ref-type="bibr">84</xref>)<break/>(<xref rid="B85" ref-type="bibr">85</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Acinetobacter baumannii</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">Ata, FilF, and Nucab<break/>Ata</td><td valign="middle" align="center" rowspan="1" colspan="1">Preclinical<break/>Preclinical</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B86" ref-type="bibr">86</xref>)<break/>(<xref rid="B87" ref-type="bibr">87</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Acinetobacter baumannii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">EpsA, CsuB<break/>FilF</td><td valign="top" align="center" rowspan="1" colspan="1">In silico<break/>In silico</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B88" ref-type="bibr">88</xref>)<break/>(<xref rid="B89" ref-type="bibr">89</xref>)</td></tr></tbody></table></table-wrap><sec id="s3_1"><label>3.1</label><title>
<italic toggle="yes">Streptococcus pneumoniae</italic> (pneumococcus)</title><p>
<italic toggle="yes">Streptococcus pneumoniae</italic> remains a significant global health burden, causing a range of severe infections, including pneumonia, meningitis, and sepsis. While pneumococcal conjugate vaccines (PCVs) have significantly reduced the incidence of pneumococcal disease, serotype diversity and the emergence of non-vaccine serotypes limit their effectiveness (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>).</p><p>Peptide vaccines offer a promising alternative by targeting conserved antigens present across multiple pneumococcal strains. This approach has the potential to provide broader protection against a wider range of serotypes, including those not covered by current vaccines. PspA (Pneumococcal Surface Protein A) is the most promising vaccine candidate (<xref rid="B92" ref-type="bibr">92</xref>). This protein&#8212;along with several other surface proteins&#8212;is highly conserved across pneumococcal strains and is recognized by both B and T-cells. Recently Bahadori et&#160;al. demonstrated the efficacy of the fusion PhtD-PspA-PspC-based peptide vaccine in inducing protective antibody responses and improving survival in animal models of pneumococcal infection in a preclinical study (<xref rid="B56" ref-type="bibr">56</xref>). Researchers have also conducted clinical trials combining the peptide vaccine and the pneumococcal conjugate vaccine for greater efficacy (<xref rid="B60" ref-type="bibr">60</xref>&#8211;<xref rid="B62" ref-type="bibr">62</xref>). However the multiepitope peptide vaccine against <italic toggle="yes">Streptococcus pneumoniae</italic> showed limited efficacy in a clinical trial for otitis media, likely due to antigenic polymorphism among strains. The selected epitopes did not cover the full antigenic diversity, resulting in weak cross-protection. Additionally, synthetic peptides may fail to replicate the native structure of full-length proteins, reducing their immunogenicity (<xref rid="B62" ref-type="bibr">62</xref>). Preclinical and clinical trials are still ongoing in this field, and if successful, peptide vaccines could provide a valuable tool in the fight against pneumococcal disease, providing broader protection and overcoming the limitations of current vaccine strategies.</p></sec><sec id="s3_2"><label>3.2</label><title>Staphylococcus aureus</title><p>
<italic toggle="yes">Staphylococcus aureus</italic>, particularly <italic toggle="yes">methicillin-resistant S. aureus</italic> (MRSA), remains a significant cause of hospital-acquired infections worldwide. Its ability to form biofilms, evade host immune responses, and develop resistance to multiple antibiotics has made it a challenging pathogen to combat (<xref rid="B93" ref-type="bibr">93</xref>).</p><p>Peptide-based vaccines represent a promising approach to combat <italic toggle="yes">Staphylococcus aureus</italic> infections by targeting key virulence factors to elicit robust immune responses and prevent bacterial colonization. Notably, clumping factors A and B (ClfA and ClfB) have emerged as important targets, as explored by Dey et&#160;al. ClfA facilitates bacterial adhesion to host tissues, while ClfB promotes attachment to nasal corneocytes and triggers human platelet aggregation. These antigens are both highly immunogenic and conserved, making them suitable candidates for vaccine development, especially against multidrug-resistant strains (<xref rid="B63" ref-type="bibr">63</xref>). Also, the newest study developed a peptide vaccine using B and T-cell epitopes from MABC, NABC, and PIc proteins to combat <italic toggle="yes">Staphylococcus aureus</italic>. Mice immunized with this vaccine showed the best skin lesion healing, with high IgG levels, increased INF-&#947;, and enhanced CD<sub>4</sub>/CD<sub>8</sub> T-cell counts. This approach improved both humoral and cellular immunity, demonstrating promising results for <italic toggle="yes">S. aureus</italic> vaccine development (<xref rid="B65" ref-type="bibr">65</xref>).</p><p>Several multi-antigenic peptide vaccines have been evaluated in preoperative settings. For example, the V710 vaccine targeting IsdB did not reduce the incidence of postoperative infections in cardiac surgery patients and was paradoxically associated with increased mortality in those who became infected&#8212;likely due to insufficient preexisting IL-2 and IL-17 responses (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B94" ref-type="bibr">94</xref>). Conversely, the rFSAV vaccine, which incorporates five different antigens, demonstrated good safety and strong, rapid humoral responses in a phase II clinical trial among patients undergoing elective orthopedic surgery (<xref rid="B70" ref-type="bibr">70</xref>). These findings highlight the challenges inherent in developing effective vaccines against <italic toggle="yes">S. aureus</italic>, including the need for appropriate antigen selection and consideration of host immune profiles.</p><p>Despite these findings, no peptide-based <italic toggle="yes">S. aureus</italic> vaccine has yet reached clinical application, underscoring the need for further experimental and clinical investigations (<xref rid="B95" ref-type="bibr">95</xref>).</p></sec><sec id="s3_3"><label>3.3</label><title>Pseudomonas aeruginosa</title><p>
<italic toggle="yes">Pseudomonas aeruginosa</italic> is a versatile opportunistic pathogen that can cause a wide range of infections, particularly in immunocompromised individuals. Its intrinsic antibiotic resistance and ability to form biofilms make it a significant challenge in healthcare settings (<xref rid="B96" ref-type="bibr">96</xref>).</p><p>Peptide vaccines represent a promising strategy to combat <italic toggle="yes">P. aeruginosa</italic> infections. Key targets for peptide-based vaccines against <italic toggle="yes">P. aeruginosa</italic> include outer membrane proteins (OMPs) and also the receptor-binding domains (RBD) of pili. Studies to develop a peptide vaccine against RBD have been conducted in the past (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>). Recently, in the study by Adlbrecht et&#160;al., a peptide vaccine against OprI and OprF was evaluated in phase II and III clinical trials, and it showed that while the vaccine was highly immunogenic, it did not reduce mortality from <italic toggle="yes">Pseudomonas aeruginosa</italic> (<xref rid="B72" ref-type="bibr">72</xref>). Additionally, Roy et&#160;al. designed an in silico multiepitope peptide vaccine targeting the OprF and OprE proteins of Pseudomonas aeruginosa, which are conserved across various serogroups and phenotypically stable within biofilms. While the computational predictions regarding immunogenicity, antigenicity, and safety were promising, no experimental validation has been reported to date. Therefore, extensive preclinical and clinical studies are still required to confirm its real-world efficacy (<xref rid="B77" ref-type="bibr">77</xref>). Currently, more clinical trials are underway to assess the safety and immunogenicity of peptide vaccine candidates against <italic toggle="yes">P. aeruginosa</italic>. If successful, these vaccines could provide much-needed protection for high-risk individuals, particularly those with underlying medical conditions or undergoing invasive procedures.</p></sec><sec id="s3_4"><label>3.4</label><title>Enterococcus faecium</title><p>
<italic toggle="yes">Vancomycin-resistant Enterococcus faecium</italic> (VRE) has emerged as a significant healthcare-associated pathogen, causing a range of serious infections, including bloodstream infections, surgical site infections, and endocarditis. The increasing prevalence of VRE, coupled with its resistance to multiple antibiotics, has necessitated the development of novel therapeutic strategies (<xref rid="B99" ref-type="bibr">99</xref>).</p><p>Peptide vaccines provide a new potential strategy for the prevention of VRE infections. These vaccines may target surface proteins, such as Penicillin-Binding Protein 5 (PBP5), which is necessary for the cell wall strength and stability, inducing specific immune responses neutralizing bacteria, and preventing their biofilm formation. Since this protein is an important metabolic target for beta-lactam antibiotic resistance, peptide vaccines against its epitopes can be a preventive measure (<xref rid="B100" ref-type="bibr">100</xref>). Additionally, this protein&#8217;s multiepitope vaccine with B-cell and T-cell epitopes can elicit both humoral and cellular immune responses, which Dey et&#160;al. evaluated in silico, and were promising for experimental testing. Humoral immunity, mediated by antibodies, can neutralize VRE and promote its clearance by phagocytic cells. Cellular immunity, mediated by T-cells, can eliminate infected cells and provide long-lasting protection (<xref rid="B79" ref-type="bibr">79</xref>). By enhancing immune system recognition and overcoming immune evasion mechanisms, peptide vaccines have the potential to improve outcomes for patients infected with VRE. Although preclinical and clinical research is needed for a vaccine against this bacterium, they represent a promising strategy to combat this challenging pathogen.</p></sec><sec id="s3_5"><label>3.5</label><title>Klebsiella pneumoniae</title><p>Carbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a major global health threat, causing severe infections such as pneumonia, bloodstream infections, and urinary tract infections (UTIs). The increasing prevalence of CRKP, coupled with its resistance to multiple antibiotics, has led to significant morbidity and mortality (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>).</p><p>Unfortunately, there is no effective vaccine available against <italic toggle="yes">Klebsiella pneumoniae</italic> (<xref rid="B103" ref-type="bibr">103</xref>). Peptide vaccines are considered promising approaches for fighting CRKP infections. Major candidates for peptide-based vaccines against CRKP include outer membrane proteins (OMPs) such as OmpA which are involved in bacterial survival and virulence. In a study conducted by Liao et&#160;al., was produced a peptide vaccine to target the OmpA-OmpW-FepA combination protein and then administered that vaccine to mice. Induced by such antigens, the peptide vaccine confers the capabilities of opsonization of bacteria by antibodies; they make them more amenable to clearance by an immune cell and evoke IgG antibodies above any other tested immunoglobulins (<xref rid="B81" ref-type="bibr">81</xref>). These peptide vaccines may be used against CRKP, which will improve the outcomes. However, we need more studies to test the safety and efficacy of these peptide vaccines.</p></sec><sec id="s3_6"><label>3.6</label><title>Acinetobacter baumannii</title><p>
<italic toggle="yes">Acinetobacter baumannii</italic> is a gram-negative bacterium with increasing trends toward multidrug resistance, which has constituted a severe health threat worldwide during recent years. This microorganism is thus quasi-invincible due to its ability to form biofilm and its resistance to most known antibiotics, including last-resort antimicrobials including colistin (<xref rid="B104" ref-type="bibr">104</xref>).</p><p>One of the most interesting strategies to overcome the problems caused by these bacteria is peptide vaccines that important approach is in the targeting of biofilm-related proteins such as Ata, FilF, and Nucab. They are important in bacterial adhesion, biofilm development, and immune evasion (<xref rid="B105" ref-type="bibr">105</xref>). Ren et al. developed peptide vaccines targeting these antigens, which inhibit biofilm formation, reduce bacterial colonization, and accelerate immune clearance. In addition, this study developed a peptide vaccine that generated opsonizing antibodies capable of promoting phagocytosis and clearance of developing bacterial infections. This is especially crucial in the setting of chronic infections, in which bacteria can avoid host defenses (<xref rid="B86" ref-type="bibr">86</xref>). Peptide vaccines are in progress to combat A. baumannii and improve patient outcomes. They are a potentially powerful weapon against this ornery bug. Many need to be further tested for safety and effectiveness.</p></sec></sec><sec id="s4"><label>4</label><title>Preclinical and clinical evaluation of peptide vaccines against bacterial infections</title><p>Significant progress has been made in the development of peptide vaccines for bacterial infections, and promising results have been obtained from both preclinical and&#8194;clinical studies.</p><sec id="s4_1"><label>4.1</label><title>Animal models</title><p>Mice, non-human primates, and other animal models are invaluable for assessing immunogenicity and efficacy&#8194;of peptide vaccines. Such models enable studies to study the induction of particular immune responses,&#8194;such as T-cell activation, antibody production and cytokine profiles. For bacterial pathogens, effector-encoded peptide vaccines have shown promise in animal&#8194;models, including for organisms such as <italic toggle="yes">Staphylococcus aureus</italic>. <italic toggle="yes">S. aureus</italic> peptide vaccines reduce bacterial load and&#8194;improve survival in animal models of infection (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B106" ref-type="bibr">106</xref>). While animal models provide valuable insights, it is important to acknowledge their limitations. Differences in immune responses between animals and humans can impact the interpretation of preclinical data. Therefore, studies must carefully consider the selection of appropriate animal models and how to apply findings to human populations (<xref rid="B107" ref-type="bibr">107</xref>).</p></sec><sec id="s4_2"><label>4.2</label><title>Clinical trials</title><p>The transition from preclinical studies to clinical trials is a critical step in the development of peptide vaccines. Phase I clinical trials focus on assessing the safety and tolerability of the vaccine in a small group of healthy volunteers. Phase II trials involve larger groups of participants and aim to determine the optimal dose and evaluate the vaccine&#8217;s effectiveness. Phase III trials, the final stage of clinical development, involve large-scale randomized controlled trials to confirm the vaccine&#8217;s efficacy and safety in diverse populations. Several peptide-based vaccines targeting bacterial infections are currently undergoing clinical trials, which were mentioned earlier. For example, peptide vaccines for <italic toggle="yes">Pseudomonas aeruginosa</italic> have shown promising safety profiles in Phase I trials. Ongoing Phase II trials are evaluating their immunogenicity and efficacy in larger populations. While these early-phase clinical trials have shown encouraging results, challenges remain in advancing peptide vaccines to Phase III trials. Factors such as peptide stability, immunogenicity, and the development of effective adjuvants and delivery systems are crucial for generalizing preclinical findings into clinical applications (<xref rid="B108" ref-type="bibr">108</xref>).</p></sec></sec><sec id="s5"><label>5</label><title>A Critical appraisal of the safety, stability, and manufacturability of peptide vaccines</title><sec id="s5_1"><label>5.1</label><title>Safety considerations</title><p>Peptide vaccines have unprecedented safety over traditional vaccines because they are well-defined in their composition. However, the potential risk of autoimmune reactions and off-target effects is a cautious approach. If administered, peptides are highly homologous with host proteins, autoimmunity might develop. The risk of cross-reactivity has been mitigated through careful epitope selection strategies that include targeting sequences with minimal structural similarity to self-antigens. Rigorous preclinical testing &#8212; including evaluation of the long-term immune response and assessment of delayed adverse events&#8194;&#8212; is important in these discussions to ensure safety (<xref rid="B109" ref-type="bibr">109</xref>). However, advanced bioinformatic tools and structural analyses may also be used to detect peptides with low sequence homology to host proteins. This will lower the possibility of autoimmune reactions (<xref rid="B110" ref-type="bibr">110</xref>). However, if not carefully characterized, off-target effects where the immune response targets unrelated strains of bacteria and other commensal microbiota can also pose potential safety issues. Utilizing pathogen-specific peptide sequences and limiting structural similarities with commensal bacteria might mitigate these dangers (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>).</p></sec><sec id="s5_2"><label>5.2</label><title>Enhanced stability for improved logistics</title><p>Peptide vaccines provide significant logistical advantages in stability and storage, particularly in resource-limited environments. Unlike live-attenuated or inactivated vaccines, which often cause stringent cold-chain logistics (<xref rid="B113" ref-type="bibr">113</xref>), synthetic peptides exhibit greater stability at room temperature or require only moderate refrigeration. Lyophilization (freeze-drying) further extends shelf life, simplifying distribution and minimizing associated costs. Recent studies demonstrate the viability of specific peptide formulations under diverse storage conditions for extended durations. It&#8217;s particularly helpful for deploying them in remote regions (<xref rid="B114" ref-type="bibr">114</xref>).</p></sec><sec id="s5_3"><label>5.3</label><title>Simplified manufacturing and scalability</title><p>Peptide vaccines benefit from streamlined manufacturing processes compared to conventional vaccines. Unlike traditional methods rely on pathogen cultivation, peptide vaccines can be produced through chemical synthesis or recombinant DNA technology. This approach gives greater control over production, which helps achieve high purity and consistency, reduces costs, and speeds up vaccine development. However, scaling up peptide synthesis presents challenges, including potential batch-to-batch variability and high cost influenced by peptide length and complexity. Advancements in automated synthesis techniques and cost-effective production methods are addressing these limitations, which pave the way for wider use and large-scale production of peptide vaccines (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>).</p></sec></sec><sec id="s6"><label>6</label><title>Future directions in peptide vaccine development for bacterial infections</title><p>Peptide vaccines are promising tools for the prevention and management of bacterial infections, with ongoing advances in bioinformatics, immunology, and delivery technologies forming the future of their development.</p><sec id="s6_1"><label>6.1</label><title>Innovations in peptide design; bioinformatics and artificial intelligence</title><p>Due to the development of immunoinformatic tools, the implementation of&#8194;computational biology has primarily eased the way in the advancement of peptide vaccine development. High-throughput sequencing and structural biology data can be integrated by these technologies to map&#8194;the immunogenic bacterial epitopes. Using these tools, researchers can predict B-cell and T-cell epitopes, model peptide&#8211;MHC and peptide&#8211;TCR interactions, and determine binding affinities&#8194;and epitope stability. Machine learning can help guide this step by finding conserved&#8194;peptides across multiple strains of bacteria to develop vaccines capable of eliciting long-lived and specific immune responses (<xref rid="B117" ref-type="bibr">117</xref>&#8211;<xref rid="B119" ref-type="bibr">119</xref>).</p><p>In recent years, artificial intelligence (AI) has played a transformative role in vaccine design by streamlining several key steps such as antigen selection, epitope prioritization, and adjuvant discovery. Machine learning and deep learning algorithms analyze genomic sequences, protein structures, and immune system interactions to assess immunogenicity and optimize candidate peptides. These AI-driven methods not only reduce the time and cost of vaccine development but also improve precision by integrating emerging technologies like single-cell omics and synthetic biology. Despite challenges such as data heterogeneity and interpretability of models, the incorporation of AI into vaccine research represents a promising approach to accelerate the design of safe and effective peptide vaccines against a broad range of infectious diseases (<xref rid="B120" ref-type="bibr">120</xref>).</p></sec><sec id="s6_2"><label>6.2</label><title>Personalized peptide vaccines</title><p>The concept of personalized medicine is being applied more often to vaccine development. Differences in immune response among individuals, often due to genetic differences in HLA allele distribution, influence peptide presentation and recognition. Tuning frequencies for specific human genetic profiles can rescue vaccine efficacy and reduce their unwanted effects. This is especially useful for high-risk groups, including healthcare workers and people with immunodeficiency (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>) (<xref rid="B121" ref-type="bibr">121</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Strategies in peptide vaccine design and application. The figure illustrates key approaches in developing peptide vaccines, centered around antigen-presenting cells that process peptides to activate T-cell immunity. Represented vaccine modalities include linear peptides, cyclic peptides, and synthetic long peptides (SLPs) incorporating both B- and T-cell epitopes. Genomic advances enable personalized vaccines tailored to individual genetic profiles. Delivery platforms (liposomes, nanocarriers, microneedle patches, virus-like particles) and adjuvants (e.g., TLR agonists) enhance immunogenicity. The development pipeline spans in silico epitope prediction, preclinical testing, and clinical trials. Emerging strategies&#8212;such as antibiotic-conjugated peptide vaccines&#8212;highlight combinatorial approaches to boost efficacy and counter antimicrobial resistance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-16-1567584-g002.jpg"/></fig></sec><sec id="s6_3"><label>6.3</label><title>Next-generation delivery systems</title><p>Delivery System of the Next Generation Improving peptide stability and immunogenicity by optimizing vaccine delivery systems is of great significance. Innovative approaches for stable, efficient delivery of peptide vaccines are emerging, such as with virus-like particles (VLPs) and microneedle patches (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). Virus-like particles serve as efficient delivery systems for peptide vaccines by mimicking the structure of viruses while lacking genetic material, allowing safe presentation of antigens to immune cells. VLPs have been modified to&#8194;present peptide epitopes on their surface to promote antigen uptake and immune activation. This approach has shown promising efficacy against preclinical models and&#8194;is currently being evaluated for various infectious diseases (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B122" ref-type="bibr">122</xref>). Microneedle patches penetrate the outer layers of the skin and deliver their payloads&#8212;such as peptide antigens&#8212;directly to dendritic cells in the dermis in a minimally invasive manner. By targeting these key antigen-presenting cells, microneedles facilitate robust immune activation. Moreover, due to their ease of administration, pain-free application, and potential for self-use, microneedle technologies significantly improve vaccine accessibility and compliance, particularly in low-resource settings (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B123" ref-type="bibr">123</xref>).</p></sec><sec id="s6_4"><label>6.4</label><title>Combination therapies</title><p>As shown in <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>, combining peptide vaccines with antibiotics or other vaccines can enhance their efficacy and expand their activity. For infections resistant to antibiotics, combining peptide vaccines with them can reduce bacterial load and limit the rise of drug-resistant strains (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B124" ref-type="bibr">124</xref>). Additionally, combining peptide vaccines with other vaccine platforms, such as conjugate vaccines, can provide broader immune coverage against complex pathogens. In this regard, Laura L. Hammitt and colleagues conducted a clinical trial based on a protein-based pneumococcal vaccine (dPly/PhtD) containing pneumolysin toxoid and pneumococcal histidine triple protein D (<xref rid="B62" ref-type="bibr">62</xref>).</p></sec><sec id="s6_5"><label>6.5</label><title>Harnessing the power of immunomodulation</title><p>Combining peptide vaccines with immunomodulators, such as checkpoint inhibitors, can amplify immune responses. Checkpoint inhibitors can enhance T-cell responses, particularly beneficial for chronic bacterial infections that require a strong cell-mediated immune response. Such combination therapies may allow for lower antibiotic doses, which could reduce side effects and the risk of antibiotic resistance (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>).</p></sec></sec><sec sec-type="conclusions" id="s7"><label>7</label><title>Conclusion</title><p>Peptide vaccines offer a promising approach to combat bacterial infections. By targeting specific antigens, these vaccines can induce targeted immune responses, enhancing the body&#8217;s ability to recognize and eliminate bacterial pathogens. Key advantages include rapid production, cost-effectiveness, and suitability for immunocompromised individuals. However, challenges such as improving immunogenicity, stability, and delivery methods remain. Ongoing research is focused on optimizing peptide design, developing advanced delivery systems, and exploring combination therapies to enhance vaccine efficacy. With continued advancements, peptide vaccines have the potential to become a crucial tool in the struggle against antibiotic resistance and emerging infectious diseases.</p></sec></body><back><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>FTR: Visualization, Writing &#8211; original draft. NS: Writing &#8211; original draft. AE: Writing &#8211; original draft. DH: Writing &#8211; review &amp; editing. RB: Conceptualization, Supervision, Validation, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that Generative AI was used in the creation of this manuscript. The author(s) declare that generative AI was used to assist with language editing and refinement of this manuscript. All AI-processed content was carefully reviewed and approved by the authors, who take full responsibility for the work.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergstrom</surname><given-names>C</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>NO</given-names></name><name name-style="western"><surname>Kubicek-Sutherland</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Stromberg</surname><given-names>ZR</given-names></name></person-group>. <article-title>mRNA vaccine platforms to prevent bacterial infections</article-title>. <source>Trends Mol Med</source>. (<year>2024</year>) <volume>30</volume>:<page-range>524&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molmed.2024.02.013</pub-id><pub-id pub-id-type="pmid">38485647</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikuta</surname><given-names>KS</given-names></name><name name-style="western"><surname>Swetschinski</surname><given-names>LR</given-names></name><name name-style="western"><surname>Robles Aguilar</surname><given-names>G</given-names></name><name name-style="western"><surname>Sharara</surname><given-names>F</given-names></name><name name-style="western"><surname>Mestrovic</surname><given-names>T</given-names></name><name name-style="western"><surname>Gray</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet</source>. (<year>2022</year>) <volume>400</volume>:<page-range>2221&#8211;48</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(22)02185-7</pub-id><pub-id pub-id-type="pmcid">PMC9763654</pub-id><pub-id pub-id-type="pmid">36423648</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dheda</surname><given-names>K</given-names></name><name name-style="western"><surname>Makambwa</surname><given-names>E</given-names></name><name name-style="western"><surname>Esmail</surname><given-names>A</given-names></name></person-group>. <article-title>The great masquerader: tuberculosis presenting as community-acquired pneumonia</article-title>. <source>Semin Respir Crit Care Med</source>. (<year>2020</year>) <volume>41</volume>:<fpage>592</fpage>&#8211;<lpage>604</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1055/s-0040-1710583</pub-id><pub-id pub-id-type="pmid">32564347</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzoamaka</surname><given-names>M</given-names></name><name name-style="western"><surname>Ngozi</surname><given-names>O</given-names></name><name name-style="western"><surname>Johnbull</surname><given-names>OS</given-names></name><name name-style="western"><surname>Martin</surname><given-names>O</given-names></name></person-group>. <article-title>Bacterial etiology of lower respiratory tract infections and their antimicrobial susceptibility</article-title>. <source>Am J Med Sci</source>. (<year>2017</year>) <volume>354</volume>:<page-range>471&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.amjms.2017.06.025</pub-id><pub-id pub-id-type="pmid">29173358</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanquet</surname><given-names>G</given-names></name><name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></name><name name-style="western"><surname>Vietri</surname><given-names>J</given-names></name><name name-style="western"><surname>Sep&#250;lveda-Pach&#243;n</surname><given-names>I</given-names></name><name name-style="western"><surname>Menon</surname><given-names>S</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Best practices for identifying hospitalized lower respiratory tract infections using administrative data: a systematic literature review of validation studies</article-title>. <source>Infect Dis Ther</source>. (<year>2024</year>) <volume>13</volume>:<page-range>921&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s40121-024-00949-8</pub-id><pub-id pub-id-type="pmcid">PMC11058181</pub-id><pub-id pub-id-type="pmid">38498108</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laxminarayan</surname><given-names>R</given-names></name><name name-style="western"><surname>Matsoso</surname><given-names>P</given-names></name><name name-style="western"><surname>Pant</surname><given-names>S</given-names></name><name name-style="western"><surname>Brower</surname><given-names>C</given-names></name><name name-style="western"><surname>R&#248;ttingen</surname><given-names>J-A</given-names></name><name name-style="western"><surname>Klugman</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Access to effective antimicrobials: a worldwide challenge</article-title>. <source>Lancet</source>. (<year>2016</year>) <volume>387</volume>:<page-range>168&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(15)00474-2</pub-id><pub-id pub-id-type="pmid">26603918</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtiss</surname><given-names>R</given-names></name></person-group>. <article-title>Bacterial infectious disease control by vaccine development</article-title>. <source>J Clin investigation</source>. (<year>2002</year>) <volume>110</volume>:<page-range>1061&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI0216941</pub-id><pub-id pub-id-type="pmcid">PMC150804</pub-id><pub-id pub-id-type="pmid">12393839</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamei</surname><given-names>K</given-names></name></person-group>. <article-title>Live attenuated vaccines in patients receiving immunosuppressive agents</article-title>. <source>Pediatr Nephrology</source>. (<year>2023</year>) <volume>38</volume>:<page-range>3889&#8211;900</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00467-023-05969-z</pub-id><pub-id pub-id-type="pmcid">PMC10115603</pub-id><pub-id pub-id-type="pmid">37076756</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group>. <article-title>The advantages and disadvantages of different types of vaccines: DNA vaccine, mRNA vaccine, and inactivated vaccine</article-title>. <source>Theor Nat Sci</source>. (<year>2023</year>) <volume>6</volume>. doi:&#160;<pub-id pub-id-type="doi">10.54254/2753-8818/6/20230193</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JM</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><name name-style="western"><surname>Neeli</surname><given-names>P</given-names></name><name name-style="western"><surname>Sobhani</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1332939</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1332939</pub-id><pub-id pub-id-type="pmid">38361919</pub-id><pub-id pub-id-type="pmcid">PMC10867258</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>M</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>PA</given-names></name><name name-style="western"><surname>St&#229;hl</surname><given-names>S</given-names></name></person-group>. <article-title>Design and production of recombinant subunit vaccines</article-title>. <source>Biotechnol Appl Biochem</source>. (<year>2000</year>) <volume>32</volume>:<fpage>95</fpage>&#8211;<lpage>107</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1042/BA20000034</pub-id><pub-id pub-id-type="pmid">11001870</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullins</surname><given-names>LP</given-names></name><name name-style="western"><surname>Mason</surname><given-names>E</given-names></name><name name-style="western"><surname>Winter</surname><given-names>K</given-names></name><name name-style="western"><surname>Sadarangani</surname><given-names>M</given-names></name></person-group>. <article-title>Vaccination is an integral strategy to combat antimicrobial resistance</article-title>. <source>PLoS Pathogens</source>. (<year>2023</year>) <volume>19</volume>:<elocation-id>e1011379</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1011379</pub-id><pub-id pub-id-type="pmid">37319164</pub-id><pub-id pub-id-type="pmcid">PMC10270329</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laxminarayan</surname><given-names>R</given-names></name><name name-style="western"><surname>Duse</surname><given-names>A</given-names></name><name name-style="western"><surname>Wattal</surname><given-names>C</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Wertheim</surname><given-names>HF</given-names></name><name name-style="western"><surname>Sumpradit</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Antibiotic resistance&#8212;the need for global solutions</article-title>. <source>Lancet Infect diseases</source>. (<year>2013</year>) <volume>13</volume>:<page-range>1057&#8211;98</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(13)70318-9</pub-id><pub-id pub-id-type="pmid">24252483</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garza-Cervantes</surname><given-names>JA</given-names></name><name name-style="western"><surname>Le&#243;n-Buitimea</surname><given-names>A</given-names></name></person-group>. <article-title>Editorial: Synergistic combinatorial treatments to overcome antibiotic resistance</article-title>. <source>Front Cell Infection Microbiol</source>. (<year>2024</year>) <volume>14</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2024.1369264</pub-id><pub-id pub-id-type="pmcid">PMC10853682</pub-id><pub-id pub-id-type="pmid">38343889</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheu</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>P-R</given-names></name></person-group>. <article-title>Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options</article-title>. <source>Front microbiology</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>80</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2019.00080</pub-id><pub-id pub-id-type="pmcid">PMC6363665</pub-id><pub-id pub-id-type="pmid">30761114</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rueckert</surname><given-names>C</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>CA</given-names></name></person-group>. <article-title>Vaccines: from empirical development to rational design</article-title>. <source>PLoS pathogens</source>. (<year>2012</year>) <volume>8</volume>:<elocation-id>e1003001</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1003001</pub-id><pub-id pub-id-type="pmid">23144616</pub-id><pub-id pub-id-type="pmcid">PMC3493475</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flemming</surname><given-names>H-C</given-names></name><name name-style="western"><surname>Wingender</surname><given-names>J</given-names></name></person-group>. <article-title>The biofilm matrix</article-title>. <source>Nat Rev microbiology</source>. (<year>2010</year>) <volume>8</volume>:<page-range>623&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro2415</pub-id><pub-id pub-id-type="pmid">20676145</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name></person-group>. <article-title>Staphylococcus aureus toxins</article-title>. <source>Curr Opin microbiology</source>. (<year>2014</year>) <volume>17</volume>:<page-range>32&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.mib.2013.11.004</pub-id><pub-id pub-id-type="pmcid">PMC3942668</pub-id><pub-id pub-id-type="pmid">24581690</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Woude</surname><given-names>MW</given-names></name><name name-style="western"><surname>B&#228;umler</surname><given-names>AJ</given-names></name></person-group>. <article-title>Phase and antigenic variation in bacteria</article-title>. <source>Clin Microbiol Rev</source>. (<year>2004</year>) <volume>17</volume>:<fpage>581</fpage>&#8211;<lpage>611</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CMR.17.3.581-611.2004</pub-id><pub-id pub-id-type="pmid">15258095</pub-id><pub-id pub-id-type="pmcid">PMC452554</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name><name name-style="western"><surname>Thammavongsa</surname><given-names>V</given-names></name><name name-style="western"><surname>Schneewind</surname><given-names>O</given-names></name><name name-style="western"><surname>Missiakas</surname><given-names>D</given-names></name></person-group>. <article-title>Recurrent infections and immune evasion strategies of Staphylococcus aureus</article-title>. <source>Curr Opin microbiology</source>. (<year>2012</year>) <volume>15</volume>:<page-range>92&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.mib.2011.10.012</pub-id><pub-id pub-id-type="pmcid">PMC3538788</pub-id><pub-id pub-id-type="pmid">22088393</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>EA</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name></person-group>. <article-title>The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex</article-title>. <source>Curr Biol</source>. (<year>1998</year>) <volume>8</volume>:<page-range>709&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0960-9822(98)70278-7</pub-id><pub-id pub-id-type="pmid">9637923</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skwarczynski</surname><given-names>M</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Peptide-based synthetic vaccines</article-title>. <source>Chem science</source>. (<year>2016</year>) <volume>7</volume>:<page-range>842&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1039/C5SC03892H</pub-id><pub-id pub-id-type="pmcid">PMC5529997</pub-id><pub-id pub-id-type="pmid">28791117</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafaghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bahadori</surname><given-names>Z</given-names></name><name name-style="western"><surname>Madanchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>MM</given-names></name><name name-style="western"><surname>Shabani</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>SF</given-names></name></person-group>. <article-title>Immunoinformatics-aided design of a new multi-epitope vaccine adjuvanted with domain 4 of pneumolysin against Streptococcus pneumoniae strains</article-title>. <source>BMC Bioinf</source>. (<year>2023</year>) <volume>24</volume>:<fpage>67</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12859-023-05175-6</pub-id><pub-id pub-id-type="pmcid">PMC9951839</pub-id><pub-id pub-id-type="pmid">36829109</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasannejad-Asl</surname><given-names>B</given-names></name><name name-style="western"><surname>Pooresmaeil</surname><given-names>F</given-names></name><name name-style="western"><surname>Takamoli</surname><given-names>S</given-names></name><name name-style="western"><surname>Dabiri</surname><given-names>M</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A</given-names></name></person-group>. <article-title>Cell penetrating peptide: A potent delivery system in vaccine development</article-title>. <source>Front Pharmacol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1072685</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fphar.2022.1072685</pub-id><pub-id pub-id-type="pmid">36425579</pub-id><pub-id pub-id-type="pmcid">PMC9679422</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pati</surname><given-names>R</given-names></name><name name-style="western"><surname>Shevtsov</surname><given-names>M</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>A</given-names></name></person-group>. <article-title>Nanoparticle vaccines against infectious diseases</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>2224</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02224</pub-id><pub-id pub-id-type="pmid">30337923</pub-id><pub-id pub-id-type="pmcid">PMC6180194</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malonis</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lai</surname><given-names>JR</given-names></name><name name-style="western"><surname>Vergnolle</surname><given-names>O</given-names></name></person-group>. <article-title>Peptide-based vaccines: current progress and future challenges</article-title>. <source>Chem Rev</source>. (<year>2019</year>) <volume>120</volume>:<page-range>3210&#8211;29</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmcid">PMC7094793</pub-id><pub-id pub-id-type="pmid">31804810</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guti&#233;rrez-Mart&#237;nez</surname><given-names>E</given-names></name><name name-style="western"><surname>Plan&#232;s</surname><given-names>R</given-names></name><name name-style="western"><surname>Anselmi</surname><given-names>G</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>M</given-names></name><name name-style="western"><surname>Menezes</surname><given-names>S</given-names></name><name name-style="western"><surname>Adiko</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Cross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets</article-title>. <source>Front Immunol</source>. (<year>2015</year>) <volume>6</volume>:<elocation-id>363</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2015.00363</pub-id><pub-id pub-id-type="pmid">26236315</pub-id><pub-id pub-id-type="pmcid">PMC4505393</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wieczorek</surname><given-names>M</given-names></name><name name-style="western"><surname>Abualrous</surname><given-names>ET</given-names></name><name name-style="western"><surname>Sticht</surname><given-names>J</given-names></name><name name-style="western"><surname>&#193;lvaro-Benito</surname><given-names>M</given-names></name><name name-style="western"><surname>Stolzenberg</surname><given-names>S</given-names></name><name name-style="western"><surname>No&#233;</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<elocation-id>292</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00292</pub-id><pub-id pub-id-type="pmid">28367149</pub-id><pub-id pub-id-type="pmcid">PMC5355494</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name></person-group>. <article-title>Peptide-based vaccines for tuberculosis</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.830497</pub-id><pub-id pub-id-type="pmcid">PMC8841753</pub-id><pub-id pub-id-type="pmid">35173740</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rastogi</surname><given-names>I</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>D</given-names></name><name name-style="western"><surname>Moseman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Muralidhar</surname><given-names>A</given-names></name><name name-style="western"><surname>Potluri</surname><given-names>HK</given-names></name><name name-style="western"><surname>McNeel</surname><given-names>DG</given-names></name></person-group>. <article-title>Role of B cells as antigen presenting cells</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>954936</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.954936</pub-id><pub-id pub-id-type="pmid">36159874</pub-id><pub-id pub-id-type="pmcid">PMC9493130</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chia</surname><given-names>LY</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>PV</given-names></name><name name-style="western"><surname>Maki</surname><given-names>MAA</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>G</given-names></name><name name-style="western"><surname>Thilagar</surname><given-names>S</given-names></name></person-group>. <article-title>A review: The antiviral activity of cyclic peptides</article-title>. <source>Int J Pept Res Ther</source>. (<year>2022</year>) <volume>29</volume>:<fpage>7</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10989-022-10478-y</pub-id><pub-id pub-id-type="pmid">36471676</pub-id><pub-id pub-id-type="pmcid">PMC9713128</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meuleman</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>JI</given-names></name><name name-style="western"><surname>Owsianka</surname><given-names>AM</given-names></name><name name-style="western"><surname>Van de Langemheen</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>AH</given-names></name><name name-style="western"><surname>Liskamp</surname><given-names>RM</given-names></name></person-group>. <article-title>Immobilization by surface conjugation of cyclic peptides for effective mimicry of the HCV-envelope E2 protein as a strategy toward synthetic vaccines</article-title>. <source>Bioconjugate Chem</source>. (<year>2018</year>) <volume>29</volume>:<page-range>1091&#8211;101</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.bioconjchem.7b00755</pub-id><pub-id pub-id-type="pmid">29382188</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eriksson</surname><given-names>C</given-names></name><name name-style="western"><surname>Gunasekera</surname><given-names>S</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Laur&#233;n</surname><given-names>I</given-names></name><name name-style="western"><surname>Mangsbo</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Epitopes displayed in a cyclic peptide scaffold bind SARS-COV-2 antibodies</article-title>. <source>ChemBioChem</source>. (<year>2023</year>) <volume>24</volume>:<fpage>e202300103</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cbic.202300103</pub-id><pub-id pub-id-type="pmid">37021633</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sajid</surname><given-names>M</given-names></name><name name-style="western"><surname>Marriam</surname><given-names>S</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>H</given-names></name><name name-style="western"><surname>Sohail</surname><given-names>S</given-names></name><name name-style="western"><surname>Sajid</surname><given-names>M</given-names></name><name name-style="western"><surname>Sehgal</surname><given-names>SA</given-names></name></person-group>. <article-title>Epitope-based peptide vaccine design and elucidation of novel compounds against 3C like protein of SARS-CoV-2</article-title>. <source>PLoS One</source>. (<year>2022</year>) <volume>17</volume>:<elocation-id>e0264700</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0264700</pub-id><pub-id pub-id-type="pmid">35324925</pub-id><pub-id pub-id-type="pmcid">PMC8947391</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>HX</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J</given-names></name><name name-style="western"><surname>Poh</surname><given-names>CL</given-names></name></person-group>. <article-title>Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine</article-title>. <source>Med Microbiol Immunol</source>. (<year>2021</year>) <volume>210</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00430-021-00700-x</pub-id><pub-id pub-id-type="pmid">33515283</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Karkhah</surname><given-names>A</given-names></name><name name-style="western"><surname>Nouri</surname><given-names>HR</given-names></name></person-group>. <article-title>Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches</article-title>. <source>Infection Genet Evolution</source>. (<year>2017</year>) <volume>51</volume>:<page-range>227&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.meegid.2017.04.009</pub-id><pub-id pub-id-type="pmid">28411163</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mortazavi</surname><given-names>B</given-names></name><name name-style="western"><surname>Molaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Fard</surname><given-names>NA</given-names></name></person-group>. <article-title>Multi-epitopevaccines, from design to expression; an in silico approach</article-title>. <source>Hum Immunol</source>. (<year>2024</year>) <volume>85</volume>:<fpage>110804</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.humimm.2024.110804</pub-id><pub-id pub-id-type="pmid">38658216</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>T</given-names></name><name name-style="western"><surname>Ai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Advances of computational methods enhance the development of multi-epitope vaccines</article-title>. <source>Brief Bioinform</source>. (<year>2024</year>) <volume>26</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1093/bib/bbaf055</pub-id><pub-id pub-id-type="pmcid">PMC11827616</pub-id><pub-id pub-id-type="pmid">39951549</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hossen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>MN</given-names></name><name name-style="western"><surname>Haque</surname><given-names>M</given-names></name><name name-style="western"><surname>Al Arian</surname><given-names>T</given-names></name><name name-style="western"><surname>Halder</surname><given-names>SK</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Immunoinformatics-aided rational design of multiepitope-based peptide vaccine (MEBV) targeting human parainfluenza virus 3 (HPIV-3) stable proteins</article-title>. <source>J Genet Eng Biotechnol</source>. (<year>2023</year>) <volume>21</volume>:<fpage>162</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s43141-023-00623-5</pub-id><pub-id pub-id-type="pmid">38055114</pub-id><pub-id pub-id-type="pmcid">PMC10700276</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosendahl Huber</surname><given-names>S</given-names></name><name name-style="western"><surname>Camps</surname><given-names>MG</given-names></name><name name-style="western"><surname>Jacobi</surname><given-names>RH</given-names></name><name name-style="western"><surname>Mouthaan</surname><given-names>J</given-names></name><name name-style="western"><surname>van Dijken</surname><given-names>H</given-names></name><name name-style="western"><surname>van Beek</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Synthetic long peptide influenza vaccine containing conserved T and B cell epitopes reduces viral load in lungs of mice and ferrets</article-title>. <source>PLoS One</source>. (<year>2015</year>) <volume>10</volume>:<elocation-id>e0127969</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0127969</pub-id><pub-id pub-id-type="pmid">26046664</pub-id><pub-id pub-id-type="pmcid">PMC4457525</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosalia</surname><given-names>RA</given-names></name><name name-style="western"><surname>Quakkelaar</surname><given-names>ED</given-names></name><name name-style="western"><surname>Redeker</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Camps</surname><given-names>M</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>JW</given-names></name><etal/></person-group>. <article-title>Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation</article-title>. <source>Eur J Immunol</source>. (<year>2013</year>) <volume>43</volume>:<page-range>2554&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.201343324</pub-id><pub-id pub-id-type="pmid">23836147</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Holden</surname><given-names>RL</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>NK</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Karver</surname><given-names>MR</given-names></name><name name-style="western"><surname>Dinter</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability</article-title>. <source>Cancer Immunol Res</source>. (<year>2018</year>) <volume>6</volume>:<page-range>1025&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0607</pub-id><pub-id pub-id-type="pmcid">PMC6247902</pub-id><pub-id pub-id-type="pmid">29915023</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>NI</given-names></name><name name-style="western"><surname>Huis in&#8217;t Veld</surname><given-names>LG</given-names></name><name name-style="western"><surname>Raaijmakers</surname><given-names>TK</given-names></name><name name-style="western"><surname>Adema</surname><given-names>GJ</given-names></name></person-group>. <article-title>Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines</article-title>? <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>2874</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02874</pub-id><pub-id pub-id-type="pmid">30619259</pub-id><pub-id pub-id-type="pmcid">PMC6300500</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guimar&#227;es</surname><given-names>LE</given-names></name><name name-style="western"><surname>Baker</surname><given-names>B</given-names></name><name name-style="western"><surname>Perricone</surname><given-names>C</given-names></name><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Vaccines, adjuvants and autoimmunity</article-title>. <source>Pharmacol Res</source>. (<year>2015</year>) <volume>100</volume>:<fpage>190</fpage>&#8211;<lpage>209</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.phrs.2015.08.003</pub-id><pub-id pub-id-type="pmid">26275795</pub-id><pub-id pub-id-type="pmcid">PMC7129276</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azmi</surname><given-names>F</given-names></name><name name-style="western"><surname>Ahmad Fuaad</surname><given-names>AA</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Recent progress in adjuvant discovery for peptide-based subunit vaccines</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2014</year>) <volume>10</volume>:<page-range>778&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.27332</pub-id><pub-id pub-id-type="pmcid">PMC4130256</pub-id><pub-id pub-id-type="pmid">24300669</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleemi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name></person-group>. <article-title>Current progress in the science of novel adjuvant nano-vaccine-induced protective immune responses</article-title>. <source>Pathogens</source>. (<year>2024</year>) <volume>13</volume>:<fpage>441</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pathogens13060441</pub-id><pub-id pub-id-type="pmid">38921739</pub-id><pub-id pub-id-type="pmcid">PMC11206999</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name></person-group>. <article-title>Peptide-enabled targeted delivery systems for therapeutic applications</article-title>. <source>Front Bioengineering Biotechnol</source>. (<year>2021</year>) <volume>9</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fbioe.2021.701504</pub-id><pub-id pub-id-type="pmcid">PMC8281044</pub-id><pub-id pub-id-type="pmid">34277592</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Micoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Stefanetti</surname><given-names>G</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>CA</given-names></name></person-group>. <article-title>Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines</article-title>. <source>Front Mol Biosci</source>. (<year>2023</year>) <volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmolb.2023.1201693</pub-id><pub-id pub-id-type="pmcid">PMC10227950</pub-id><pub-id pub-id-type="pmid">37261327</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobrovolskaia</surname><given-names>MA</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>SE</given-names></name></person-group>. <article-title>Immunological properties of engineered nanomaterials</article-title>. <source>Nat nanotechnology</source>. (<year>2007</year>) <volume>2</volume>:<page-range>469&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nnano.2007.223</pub-id><pub-id pub-id-type="pmid">18654343</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>M</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name></person-group>. <article-title>Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics</article-title>. <source>Exp Mol Med</source>. (<year>2023</year>) <volume>55</volume>:<page-range>2085&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s12276-023-01086-x</pub-id><pub-id pub-id-type="pmcid">PMC10618257</pub-id><pub-id pub-id-type="pmid">37779140</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagan</surname><given-names>R</given-names></name><name name-style="western"><surname>van der Beek</surname><given-names>BA</given-names></name></person-group>. <article-title>Immune response to the 13-valent pneumococcal conjugate vaccine is reduced in infants immunized during the respiratory viral season</article-title>. <source>Clin Infect Dis</source>. (<year>2024</year>), <fpage>ciae619</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/ciae619</pub-id><pub-id pub-id-type="pmid">39686809</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pichichero</surname><given-names>ME</given-names></name></person-group>. <article-title>Protein carriers of conjugate vaccines: characteristics, development, and clinical trials</article-title>. <source>Hum vaccines immunotherapeutics</source>. (<year>2013</year>) <volume>9</volume>:<page-range>2505&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.26109</pub-id><pub-id pub-id-type="pmcid">PMC4162048</pub-id><pub-id pub-id-type="pmid">23955057</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>R</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>P</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kushwaha</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Development of a Conserved Chimeric Vaccine for Induction of Strong Immune Response against Staphylococcus aureus Using Immunoinformatics Approaches</article-title>. <source>Vaccines (Basel)</source>. (<year>2021</year>) <volume>9</volume>:<page-range>1038&#8211;58</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9091038</pub-id><pub-id pub-id-type="pmcid">PMC8470666</pub-id><pub-id pub-id-type="pmid">34579274</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolla</surname><given-names>HB</given-names></name><name name-style="western"><surname>Makam</surname><given-names>SS</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>PN</given-names></name></person-group>. <article-title>Mapping of conserved immunodominant epitope peptides in the outer membrane porin (Omp) L of prominent Enterobacteriaceae pathogens associated with gastrointestinal infections</article-title>. <source>J Genet Eng Biotechnol</source>. (<year>2023</year>) <volume>21</volume>:<fpage>146</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s43141-023-00622-6</pub-id><pub-id pub-id-type="pmid">38012455</pub-id><pub-id pub-id-type="pmcid">PMC10682294</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafaghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bahadori</surname><given-names>Z</given-names></name><name name-style="western"><surname>Barzi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Afshari</surname><given-names>E</given-names></name><name name-style="western"><surname>Madanchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>SF</given-names></name><etal/></person-group>. <article-title>A new candidate epitope-based vaccine against PspA PhtD of Streptococcus pneumoniae: a computational experimental approach</article-title>. <source>Front Cell Infection Microbiol</source>. (<year>2023</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2023.1271143</pub-id><pub-id pub-id-type="pmcid">PMC10684780</pub-id><pub-id pub-id-type="pmid">38035337</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahadori</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shafaghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sabzevari</surname><given-names>J</given-names></name><name name-style="western"><surname>Madanchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>SF</given-names></name><etal/></person-group>. <article-title>Design, development, and assessment of a novel multi-peptide vaccine targeting PspC, PsaA, and PhtD proteins of Streptococcus pneumoniae</article-title>. <source>Int J Biol macromolecules</source>. (<year>2023</year>), <fpage>128924</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.128924</pub-id><pub-id pub-id-type="pmid">38143051</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorosti</surname><given-names>H</given-names></name><name name-style="western"><surname>Nezafat</surname><given-names>N</given-names></name><name name-style="western"><surname>Heidari</surname><given-names>R</given-names></name><name name-style="western"><surname>Ghoshoon</surname><given-names>MB</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>A</given-names></name><name name-style="western"><surname>Dehshahri</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Production and immunological evaluation of epitope-based preventative pneumococcal candidate vaccine comprising immunodominant epitopes from pspA, cbpA, phtD and piuA antigens</article-title>. <source>Curr Pharm Biotechnol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>1900&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/1389201022666201231112029</pub-id><pub-id pub-id-type="pmid">33390108</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nahian</surname><given-names>M</given-names></name><name name-style="western"><surname>Shahab</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazumder</surname><given-names>L</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>JIN</given-names></name><name name-style="western"><surname>Banu</surname><given-names>TA</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>In silico design of an epitope-based vaccine against PspC in Streptococcus pneumoniae using reverse vaccinology</article-title>. <source>J Genet Eng Biotechnol</source>. (<year>2023</year>) <volume>21</volume>:<fpage>166</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s43141-023-00604-8</pub-id><pub-id pub-id-type="pmid">38085389</pub-id><pub-id pub-id-type="pmcid">PMC10716094</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bologa</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamtchoua</surname><given-names>T</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>R</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>B</given-names></name><name name-style="western"><surname>Bixler</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine</article-title>. <source>Vaccine</source>. (<year>2012</year>) <volume>30</volume>:<page-range>7461&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.076</pub-id><pub-id pub-id-type="pmid">23123106</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>WA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>R</given-names></name></person-group>. <article-title>Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study</article-title>. <source>Vaccine</source>. (<year>2015</year>) <volume>33</volume>:<page-range>4610&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.078</pub-id><pub-id pub-id-type="pmid">26143615</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pauksens</surname><given-names>K</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Caubet</surname><given-names>M</given-names></name><name name-style="western"><surname>Pascal</surname><given-names>TG</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>P</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults</article-title>. <source>Clin Vaccine Immunol</source>. (<year>2014</year>) <volume>21</volume>:<page-range>651&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00807-13</pub-id><pub-id pub-id-type="pmcid">PMC4018883</pub-id><pub-id pub-id-type="pmid">24599529</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammitt</surname><given-names>LL</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>JC</given-names></name><name name-style="western"><surname>Borys</surname><given-names>D</given-names></name><name name-style="western"><surname>Weatherholtz</surname><given-names>RC</given-names></name><name name-style="western"><surname>Reid</surname><given-names>R</given-names></name><name name-style="western"><surname>Goklish</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study</article-title>. <source>Vaccine</source>. (<year>2019</year>) <volume>37</volume>:<page-range>7482&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.09.076</pub-id><pub-id pub-id-type="pmid">31629570</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Patro</surname><given-names>S</given-names></name><name name-style="western"><surname>Kushwaha</surname><given-names>GS</given-names></name><name name-style="western"><surname>Misra</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>B and T cell epitope-based peptides predicted from clumping factor protein of Staphylococcus aureus as vaccine targets</article-title>. <source>Microbial pathogenesis</source>. (<year>2021</year>) <volume>160</volume>:<fpage>105171</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.micpath.2021.105171</pub-id><pub-id pub-id-type="pmid">34481860</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococci infection</article-title>. <source>Vaccine</source>. (<year>2006</year>) <volume>24</volume>:<page-range>1117&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.09.004</pub-id><pub-id pub-id-type="pmid">16359760</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solyman</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hanora</surname><given-names>AS</given-names></name></person-group>. <article-title>Protection of mice vaccinated with a new B cell and T cell epitopes cocktail from staphylococcus aureus challenge in skin infection model</article-title>. <source>Curr Microbiology</source>. (<year>2025</year>) <volume>82</volume>:<fpage>128</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00284-025-04102-7</pub-id><pub-id pub-id-type="pmid">39922982</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajighahramani</surname><given-names>N</given-names></name><name name-style="western"><surname>Nezafat</surname><given-names>N</given-names></name><name name-style="western"><surname>Eslami</surname><given-names>M</given-names></name><name name-style="western"><surname>Negahdaripour</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahmatabadi</surname><given-names>SS</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>Y</given-names></name></person-group>. <article-title>Immunoinformatics analysis and in silico designing of a novel multi-epitope peptide vaccine against Staphylococcus aureus</article-title>. <source>Infect Genet Evol</source>. (<year>2017</year>) <volume>48</volume>:<fpage>83</fpage>&#8211;<lpage>94</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.meegid.2016.12.010</pub-id><pub-id pub-id-type="pmid">27989662</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>R</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Raj Takur</surname><given-names>K</given-names></name><name name-style="western"><surname>Raina</surname><given-names>V</given-names></name><name name-style="western"><surname>Misra</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>An immunoinformatics and structural vaccinology study to design a multi-epitope vaccine against Staphylococcus aureus infection</article-title>. <source>J Mol Recognit</source>. (<year>2023</year>) <volume>36</volume>:<elocation-id>e3007</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jmr.v36.4</pub-id><pub-id pub-id-type="pmid">36700877</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahir Ul Qamar</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>I</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>F</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>F</given-names></name><name name-style="western"><surname>Naz</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches</article-title>. <source>Comput Biol Med</source>. (<year>2021</year>) <volume>132</volume>:<fpage>104389</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104389</pub-id><pub-id pub-id-type="pmid">33866250</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ullah</surname><given-names>N</given-names></name><name name-style="western"><surname>Anwer</surname><given-names>F</given-names></name><name name-style="western"><surname>Ishaq</surname><given-names>Z</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>MA</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>In silico designed Staphylococcus aureus B-cell multi-epitope vaccine did not elicit antibodies against target antigens suggesting multi-domain approach</article-title>. <source>J Immunol Methods</source>. (<year>2022</year>) <volume>504</volume>:<fpage>113264</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jim.2022.113264</pub-id><pub-id pub-id-type="pmid">35341759</pub-id><pub-id pub-id-type="pmcid">PMC9040383</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>XY</given-names></name><name name-style="western"><surname>Gong</surname><given-names>MQ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Peng</surname><given-names>AQ</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial</article-title>. <source>Vaccine</source>. (<year>2023</year>) <volume>41</volume>:<page-range>5562&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2023.07.047</pub-id><pub-id pub-id-type="pmid">37516573</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeely</surname><given-names>TB</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NA</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>A</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartzel</surname><given-names>JS</given-names></name><name name-style="western"><surname>Keshari</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2014</year>) <volume>10</volume>:<page-range>3513&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.34407</pub-id><pub-id pub-id-type="pmcid">PMC4514053</pub-id><pub-id pub-id-type="pmid">25483690</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adlbrecht</surname><given-names>C</given-names></name><name name-style="western"><surname>Wurm</surname><given-names>R</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P</given-names></name><name name-style="western"><surname>Spapen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lorente</surname><given-names>JA</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients&#8212;a randomized clinical trial</article-title>. <source>Crit Care</source>. (<year>2020</year>) <volume>24</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13054-020-2792-z</pub-id><pub-id pub-id-type="pmid">32131866</pub-id><pub-id pub-id-type="pmcid">PMC7057595</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rello</surname><given-names>J</given-names></name><name name-style="western"><surname>Krenn</surname><given-names>C-G</given-names></name><name name-style="western"><surname>Locker</surname><given-names>G</given-names></name><name name-style="western"><surname>Pilger</surname><given-names>E</given-names></name><name name-style="western"><surname>Madl</surname><given-names>C</given-names></name><name name-style="western"><surname>Balica</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients</article-title>. <source>Crit Care</source>. (<year>2017</year>) <volume>21</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13054-017-1601-9</pub-id><pub-id pub-id-type="pmid">28159015</pub-id><pub-id pub-id-type="pmcid">PMC5291979</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westritschnig</surname><given-names>K</given-names></name><name name-style="western"><surname>Hochreiter</surname><given-names>R</given-names></name><name name-style="western"><surname>Wallner</surname><given-names>G</given-names></name><name name-style="western"><surname>Firbas</surname><given-names>C</given-names></name><name name-style="western"><surname>Schwameis</surname><given-names>M</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B</given-names></name></person-group>. <article-title>A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers</article-title>. <source>Hum vaccines immunotherapeutics</source>. (<year>2014</year>) <volume>10</volume>:<page-range>170&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.26565</pub-id><pub-id pub-id-type="pmcid">PMC4181012</pub-id><pub-id pub-id-type="pmid">24064511</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>RS</given-names></name></person-group>. <article-title>Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa</article-title>. <source>Chem Biol Drug Des</source>. (<year>2009</year>) <volume>74</volume>:<fpage>33</fpage>&#8211;<lpage>42</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1747-0285.2009.00825.x</pub-id><pub-id pub-id-type="pmid">19519742</pub-id><pub-id pub-id-type="pmcid">PMC2756486</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackbarth</surname><given-names>C</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>RS</given-names></name></person-group>. <article-title>Synthetic peptide vaccine development: designing dual epitopes into a single pilin peptide immunogen generates antibody cross-reactivity between two strains of Pseudomonas aeruginosa</article-title>. <source>Chem Biol Drug Des</source>. (<year>2010</year>) <volume>76</volume>:<fpage>293</fpage>&#8211;<lpage>304</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1747-0285.2010.01021.x</pub-id><pub-id pub-id-type="pmid">20807222</pub-id><pub-id pub-id-type="pmcid">PMC2949483</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>SK</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>MS</given-names></name><name name-style="western"><surname>Foyzur Raman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>R</given-names></name><name name-style="western"><surname>Rahmann</surname><given-names>Z</given-names></name><name name-style="western"><surname>Uddin PK</surname><given-names>MM</given-names></name></person-group>. <article-title>A computational approach to developing a multi-epitope vaccine for combating Pseudomonas aeruginosa&#8211;induced pneumonia and sepsis</article-title>. <source>Briefings Bioinf</source>. (<year>2024</year>) <volume>25</volume>:<fpage>bbae401</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/bib/bbae401</pub-id><pub-id pub-id-type="pmcid">PMC11318047</pub-id><pub-id pub-id-type="pmid">39133098</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elhag</surname><given-names>M</given-names></name><name name-style="western"><surname>Alaagib</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>NM</given-names></name><name name-style="western"><surname>Abubaker</surname><given-names>M</given-names></name><name name-style="western"><surname>Haroun</surname><given-names>EM</given-names></name><name name-style="western"><surname>Albagi</surname><given-names>SOA</given-names></name><etal/></person-group>. <article-title>Design of Epitope-Based Peptide Vaccine against Pseudomonas aeruginosa Fructose Bisphosphate Aldolase Protein Using Immunoinformatics</article-title>. <source>J Immunol Res</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>9475058</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2020/9475058</pub-id><pub-id pub-id-type="pmid">33204735</pub-id><pub-id pub-id-type="pmcid">PMC7666636</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Raj</surname><given-names>TK</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>T</given-names></name><name name-style="western"><surname>Jain</surname><given-names>P</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium</article-title>. <source>Gut Pathogens</source>. (<year>2022</year>) <volume>14</volume>:<fpage>21</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13099-022-00495-z</pub-id><pub-id pub-id-type="pmid">35624464</pub-id><pub-id pub-id-type="pmcid">PMC9137449</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alotaibi</surname><given-names>G</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K</given-names></name><name name-style="western"><surname>Al Mouslem</surname><given-names>AK</given-names></name><name name-style="western"><surname>Ahmad Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Naseer Abbas</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Pan genome based reverse vaccinology approach to explore Enterococcus faecium (VRE) strains for identification of novel multi-epitopes vaccine candidate</article-title>. <source>Immunobiology</source>. (<year>2022</year>) <volume>227</volume>:<fpage>152221</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.imbio.2022.152221</pub-id><pub-id pub-id-type="pmid">35483110</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>A rational designed multi-epitope vaccine elicited robust protective efficacy against Klebsiella pneumoniae lung infection</article-title>. <source>Biomedicine Pharmacotherapy</source>. (<year>2024</year>) <volume>174</volume>:<fpage>116611</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biopha.2024.116611</pub-id><pub-id pub-id-type="pmid">38643540</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goetsch</surname><given-names>L</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Plotnicky-Gilquin</surname><given-names>H</given-names></name><name name-style="western"><surname>Haeuw</surname><given-names>JF</given-names></name><name name-style="western"><surname>Aubry</surname><given-names>JP</given-names></name><name name-style="western"><surname>Beck</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Targeting of nasal mucosa-associated antigen-presenting cells <italic toggle="yes">in vivo</italic> with an outer membrane protein A derived from Klebsiella pneumoniae</article-title>. <source>Infect Immun</source>. (<year>2001</year>) <volume>69</volume>:<page-range>6434&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.69.10.6434-6444.2001</pub-id><pub-id pub-id-type="pmcid">PMC98779</pub-id><pub-id pub-id-type="pmid">11553588</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>T</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>R</given-names></name><name name-style="western"><surname>Bajoria</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kushwaha</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Immunoinformatics and molecular docking studies reveal a novel Multi-Epitope peptide vaccine against pneumonia infection</article-title>. <source>Vaccine</source>. (<year>2021</year>) <volume>39</volume>:<page-range>6221&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.09.025</pub-id><pub-id pub-id-type="pmid">34556364</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranjbarian</surname><given-names>P</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Akya</surname><given-names>A</given-names></name><name name-style="western"><surname>Heidarinia</surname><given-names>H</given-names></name><name name-style="western"><surname>Farasat</surname><given-names>A</given-names></name><name name-style="western"><surname>Rostamian</surname><given-names>M</given-names></name></person-group>. <article-title>Finding epitopes of Klebsiella pneumoniae outer membrane protein-K17 (OMPK17) and introducing a 25-mer peptide of it as a vaccine candidate</article-title>. <source>Biol (Bratisl)</source>. (<year>2023</year>), <fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11756-023-01371-0</pub-id><pub-id pub-id-type="pmcid">PMC10012306</pub-id><pub-id pub-id-type="pmid">37363641</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemati Zargaran</surname><given-names>F</given-names></name><name name-style="western"><surname>Akya</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghadiri</surname><given-names>K</given-names></name><name name-style="western"><surname>Ranjbarian</surname><given-names>P</given-names></name><name name-style="western"><surname>Rostamian</surname><given-names>M</given-names></name></person-group>. <article-title>Detecting the dominant T and B epitopes of klebsiella pneumoniae ferric enterobactin protein (FepA) and introducing a single epitopic peptide as vaccine candidate</article-title>. <source>Int J Pept Res Ther</source>. (<year>2021</year>) <volume>27</volume>:<page-range>2209&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10989-021-10247-3</pub-id><pub-id pub-id-type="pmcid">PMC8243051</pub-id><pub-id pub-id-type="pmid">34226823</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>S</given-names></name><name name-style="western"><surname>Guan</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name></person-group>. <article-title>Design and evaluation of a multi-epitope assembly peptide vaccine against Acinetobacter baumannii infection in mice</article-title>. <source>Swiss Med weekly</source>. (<year>2019</year>) <volume>149</volume>:<page-range>w20052&#8211;w</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4414/smw.2019.20052</pub-id><pub-id pub-id-type="pmid">31203576</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A short peptide of autotransporter ata is a promising protective antigen for vaccination against acinetobacter baumannii</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.884555</pub-id><pub-id pub-id-type="pmcid">PMC9043751</pub-id><pub-id pub-id-type="pmid">35493470</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name><name name-style="western"><surname>Azam</surname><given-names>SS</given-names></name></person-group>. <article-title>A novel approach of virulome based reverse vaccinology for exploring and validating peptide-based vaccine candidates against the most troublesome nosocomial pathogen: Acinetobacter baumannii</article-title>. <source>J Mol Graph Model</source>. (<year>2018</year>) <volume>83</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jmgm.2018.04.020</pub-id><pub-id pub-id-type="pmid">29753164</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>A</given-names></name><name name-style="western"><surname>Roy</surname><given-names>R</given-names></name><name name-style="western"><surname>Misra</surname><given-names>N</given-names></name><name name-style="western"><surname>Suar</surname><given-names>M</given-names></name></person-group>. <article-title>Immunoinformatics-guided designing of epitope-based subunit vaccine from Pilus assembly protein of Acinetobacter baumannii bacteria</article-title>. <source>J Immunol Methods</source>. (<year>2022</year>) <volume>508</volume>:<fpage>113325</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jim.2022.113325</pub-id><pub-id pub-id-type="pmid">35908655</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name><name name-style="western"><surname>McGee</surname><given-names>L</given-names></name><name name-style="western"><surname>Hammitt</surname><given-names>LL</given-names></name><name name-style="western"><surname>Grant</surname><given-names>LR</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>KL</given-names></name><name name-style="western"><surname>Hanage</surname><given-names>WP</given-names></name><etal/></person-group>. <article-title>Prediction of post-PCV13 pneumococcal evolution using invasive disease data enhanced by inverse-invasiveness weighting</article-title>. <source>mBio</source>. (<year>2024</year>) <volume>15</volume>:<page-range>e03355&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/mbio.03355-23</pub-id><pub-id pub-id-type="pmcid">PMC11481909</pub-id><pub-id pub-id-type="pmid">39207103</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Yao</surname><given-names>KH</given-names></name></person-group>. <article-title>Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2021</year>) <volume>17</volume>:<page-range>5628&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/21645515.2021.1985353</pub-id><pub-id pub-id-type="pmcid">PMC8903918</pub-id><pub-id pub-id-type="pmid">34726580</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandpa</surname><given-names>HH</given-names></name><name name-style="western"><surname>Panda</surname><given-names>AK</given-names></name><name name-style="western"><surname>Meena</surname><given-names>CL</given-names></name><name name-style="western"><surname>Meena</surname><given-names>J</given-names></name></person-group>. <article-title>Beyond the polysaccharide and glycoconjugate vaccines for Streptococcus pneumoniae: Does protein/peptide nanovaccines hold promises</article-title>? <source>Vaccine</source>. (<year>2023</year>) <volume>41</volume>:<page-range>7515&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2023.11.020</pub-id><pub-id pub-id-type="pmid">37980259</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushik</surname><given-names>A</given-names></name><name name-style="western"><surname>Kest</surname><given-names>H</given-names></name><name name-style="western"><surname>Sood</surname><given-names>M</given-names></name><name name-style="western"><surname>Steussy</surname><given-names>BW</given-names></name><name name-style="western"><surname>Thieman</surname><given-names>C</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name></person-group>. <article-title>Biofilm producing methicillin-resistant staphylococcus aureus (MRSA) infections in humans: clinical implications and management</article-title>. <source>Pathogens</source>. (<year>2024</year>) <volume>13</volume>:<fpage>76</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pathogens13010076</pub-id><pub-id pub-id-type="pmid">38251383</pub-id><pub-id pub-id-type="pmcid">PMC10819455</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clegg</surname><given-names>J</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>RM</given-names></name><name name-style="western"><surname>Rittenhouse</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Phogat</surname><given-names>S</given-names></name></person-group>. <article-title>Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.705360</pub-id><pub-id pub-id-type="pmcid">PMC8294057</pub-id><pub-id pub-id-type="pmid">34305945</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>PY</given-names></name></person-group>. <article-title>Immunotherapies for the prevention and treatment of Staphylococcus aureus infections: updates and challenges</article-title>. <source>Pathog Dis</source>. (<year>2023</year>) <volume>81</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1093/femspd/ftad016</pub-id><pub-id pub-id-type="pmid">37422444</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansouri</surname><given-names>E</given-names></name><name name-style="western"><surname>Blome-Eberwein</surname><given-names>S</given-names></name><name name-style="western"><surname>Gabelsberger</surname><given-names>J</given-names></name><name name-style="western"><surname>Germann</surname><given-names>G</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B-U</given-names></name></person-group>. <article-title>Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients</article-title>. <source>FEMS Immunol Med Microbiol</source>. (<year>2003</year>) <volume>37</volume>:<page-range>161&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0928-8244(03)00072-5</pub-id><pub-id pub-id-type="pmid">12832120</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>AP</given-names></name><name name-style="western"><surname>Wong</surname><given-names>WY</given-names></name><name name-style="western"><surname>Houston</surname><given-names>M</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Schweizer</surname><given-names>F</given-names></name><name name-style="western"><surname>Cachia</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Irvin</surname><given-names>RT</given-names></name><etal/></person-group>. <article-title>Interaction of the receptor binding domains of Pseudomonas aeruginosa pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: implications for synthetic vaccine design</article-title>. <source>J Mol Biol</source>. (<year>1997</year>) <volume>267</volume>:<fpage>382</fpage>&#8211;<lpage>402</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1006/jmbi.1996.0871</pub-id><pub-id pub-id-type="pmid">9096233</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>AP</given-names></name><name name-style="western"><surname>Spyracopoulos</surname><given-names>L</given-names></name><name name-style="western"><surname>Irvin</surname><given-names>RT</given-names></name><name name-style="western"><surname>Sykes</surname><given-names>BD</given-names></name></person-group>. <article-title>Backbone dynamics of a bacterially expressed peptide from the receptor binding domain of Pseudomonas aeruginosa pilin strain PAK from heteronuclear 1H-15N NMR spectroscopy</article-title>. <source>J Biomol NMR</source>. (<year>2000</year>) <volume>17</volume>:<page-range>239&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1023/A:1008311319998</pub-id><pub-id pub-id-type="pmid">10959631</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>WR</given-names></name><name name-style="western"><surname>Murray</surname><given-names>BE</given-names></name><name name-style="western"><surname>Rice</surname><given-names>LB</given-names></name><name name-style="western"><surname>Arias</surname><given-names>CA</given-names></name></person-group>. <article-title>Resistance in vancomycin-resistant enterococci. Infectious disease clinics of North America</article-title>. <year>2020</year>;<volume>34</volume>(<issue>4</issue>):<page-range>751</page-range><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.idc.2020.08.004</pub-id><pub-id pub-id-type="pmcid">PMC7640809</pub-id><pub-id pub-id-type="pmid">33131572</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunashal</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>GS</given-names></name><name name-style="western"><surname>Choy</surname><given-names>MS</given-names></name><name name-style="western"><surname>D&#8217;Andr&#233;a</surname><given-names>&#201;D</given-names></name><name name-style="western"><surname>Da Silva Santiago</surname><given-names>A</given-names></name><name name-style="western"><surname>Schoenle</surname><given-names>MV</given-names></name><etal/></person-group>. <article-title>Molecular basis of &#946;-lactam antibiotic resistance of ESKAPE bacterium E. faecium Penicillin Binding Protein PBP5</article-title>. <source>Nat Communications</source>. (<year>2023</year>) <volume>14</volume>:<fpage>4268</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-023-39966-5</pub-id><pub-id pub-id-type="pmcid">PMC10352307</pub-id><pub-id pub-id-type="pmid">37460557</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Si</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Genomic insights into the evolution and mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae co-harboring blaKPC and blaNDM: implications for public health threat mitigation</article-title>. <source>Ann Clin Microbiol Antimicrobials</source>. (<year>2024</year>) <volume>23</volume>:<fpage>27</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12941-024-00686-3</pub-id><pub-id pub-id-type="pmcid">PMC10981300</pub-id><pub-id pub-id-type="pmid">38553771</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zha</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H</given-names></name><name name-style="western"><surname>Pi</surname><given-names>J</given-names></name><name name-style="western"><surname>You</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Healthcare-associated carbapenem-resistant Klebsiella pneumoniae infections are associated with higher mortality compared to carbapenem-susceptible K. pneumoniae infections in the intensive care unit: a retrospective cohort study</article-title>. <source>J Hosp Infect</source>. (<year>2024</year>) <volume>148</volume>:<page-range>30&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jhin.2024.03.003</pub-id><pub-id pub-id-type="pmid">38513959</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehmood</surname><given-names>A</given-names></name><name name-style="western"><surname>Naseer</surname><given-names>S</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A</given-names></name><name name-style="western"><surname>Fatimah</surname><given-names>H</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>S</given-names></name><name name-style="western"><surname>Kiani</surname><given-names>AK</given-names></name></person-group>. <article-title>Identification of novel vaccine candidates against carbapenem resistant Klebsiella pneumoniae: A systematic reverse proteomic approach</article-title>. <source>Comput Biol Chem</source>. (<year>2020</year>) <volume>89</volume>:<fpage>107380</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.compbiolchem.2020.107380</pub-id><pub-id pub-id-type="pmid">32992120</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherif</surname><given-names>MM</given-names></name><name name-style="western"><surname>Elkhatib</surname><given-names>WF</given-names></name><name name-style="western"><surname>Khalaf</surname><given-names>WS</given-names></name><name name-style="western"><surname>Elleboudy</surname><given-names>NS</given-names></name><name name-style="western"><surname>Abdelaziz</surname><given-names>NA</given-names></name></person-group>. <article-title>Multidrug resistant acinetobacter baumannii biofilms: evaluation of phenotypic&#8211;genotypic association and susceptibility to cinnamic and gallic acids</article-title>. <source>Front Microbiol</source>. (<year>2021</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2021.716627</pub-id><pub-id pub-id-type="pmcid">PMC8508616</pub-id><pub-id pub-id-type="pmid">34650528</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>IL</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>DD</given-names></name></person-group>. <article-title>Unveiling the role of adhesin proteins in controlling Acinetobacter baumannii infections: a systematic review</article-title>. <source>Infection Immun</source>. (<year>2025</year>), <page-range>e00348&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.00348-24</pub-id><pub-id pub-id-type="pmcid">PMC11834437</pub-id><pub-id pub-id-type="pmid">39772848</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Immunodominance of epitopes and protective efficacy of HI antigen are differentially altered using different adjuvants in a mouse model of staphylococcus aureus bacteremia</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.684823</pub-id><pub-id pub-id-type="pmcid">PMC8190387</pub-id><pub-id pub-id-type="pmid">34122448</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mi</surname><given-names>J</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Peptides-based vaccine MP3RT induced protective immunity against mycobacterium tuberculosis infection in a humanized mouse model</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.666290</pub-id><pub-id pub-id-type="pmcid">PMC8108698</pub-id><pub-id pub-id-type="pmid">33981313</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Gong</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X-N</given-names></name></person-group>. <article-title>Research, development and clinical trials for peptide-based vaccines</article-title>. <source>Front Media SA;</source>. (<year>2022</year>), <fpage>894989</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3389/978-2-88976-146-3</pub-id><pub-id pub-id-type="pmcid">PMC9074893</pub-id><pub-id pub-id-type="pmid">35529849</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelde</surname><given-names>A</given-names></name><name name-style="western"><surname>Rammensee</surname><given-names>HG</given-names></name><name name-style="western"><surname>Walz</surname><given-names>JS</given-names></name></person-group>. <article-title>The peptide vaccine of the future</article-title>. <source>Mol Cell Proteomics</source>. (<year>2021</year>) <volume>20</volume>:<fpage>100022</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1074/mcp.R120.002309</pub-id><pub-id pub-id-type="pmid">33583769</pub-id><pub-id pub-id-type="pmcid">PMC7950068</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>R</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>L</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>F</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>M</given-names></name><name name-style="western"><surname>Passos</surname><given-names>M</given-names></name></person-group>. <article-title>Immunoinformatics design of multi-epitope peptide based vaccines against Schistosoma mansoni using transmembrane proteins a target</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.621706</pub-id><pub-id pub-id-type="pmcid">PMC7961083</pub-id><pub-id pub-id-type="pmid">33737928</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>JP</given-names></name><name name-style="western"><surname>Riemer</surname><given-names>AB</given-names></name></person-group>. <article-title>The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>883989</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.883989</pub-id><pub-id pub-id-type="pmid">35464395</pub-id><pub-id pub-id-type="pmcid">PMC9018990</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>CC</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>KS</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>KM</given-names></name><name name-style="western"><surname>Sambade</surname><given-names>M</given-names></name><name name-style="western"><surname>Beck</surname><given-names>W</given-names></name><name name-style="western"><surname>Garness</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Landscape and selection of vaccine epitopes in SARS-CoV-2</article-title>. <source>Genome Med</source>. (<year>2021</year>) <volume>13</volume>:<fpage>101</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13073-021-00910-1</pub-id><pub-id pub-id-type="pmid">34127050</pub-id><pub-id pub-id-type="pmcid">PMC8201469</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumru</surname><given-names>OS</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>SB</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DE</given-names></name><name name-style="western"><surname>Middaugh</surname><given-names>CR</given-names></name><name name-style="western"><surname>Prusik</surname><given-names>T</given-names></name><name name-style="western"><surname>Volkin</surname><given-names>DB</given-names></name></person-group>. <article-title>Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies</article-title>. <source>Biologicals</source>. (<year>2014</year>) <volume>42</volume>:<page-range>237&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biologicals.2014.05.007</pub-id><pub-id pub-id-type="pmid">24996452</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashkani</surname><given-names>EG</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>BD</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>JL</given-names></name><name name-style="western"><surname>Trevisan-Silva</surname><given-names>D</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>NE</given-names></name><name name-style="western"><surname>Chianese-Bullock</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Stability of multi-peptide vaccines in conditions enabling accessibility in limited resource settings</article-title>. <source>Int J Pept Res Ther</source>. (<year>2024</year>) <volume>30</volume>:<fpage>42</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10989-024-10620-y</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Karahan</surname><given-names>M</given-names></name></person-group>. <article-title>Synthetic Peptide Vaccine Models: Design, Synthesis, Purification and Characterization</article-title>. <publisher-loc>Boca Raton (FL)</publisher-loc>: <publisher-name>CRC Press</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>V</given-names></name><name name-style="western"><surname>Egelund</surname><given-names>PH</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>H</given-names></name><name name-style="western"><surname>Le Quement</surname><given-names>ST</given-names></name><name name-style="western"><surname>Wojcik</surname><given-names>F</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>DS</given-names></name></person-group>. <article-title>Greening the synthesis of peptide therapeutics: an industrial perspective</article-title>. <source>RSC advances</source>. (<year>2020</year>) <volume>10</volume>:<page-range>42457&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1039/D0RA07204D</pub-id><pub-id pub-id-type="pmcid">PMC9057961</pub-id><pub-id pub-id-type="pmid">35516773</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H-Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L-L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X-L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y-F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name></person-group>. <article-title>Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2</article-title>. <source>Infect Dis poverty</source>. (<year>2020</year>) <volume>9</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40249-020-00713-3</pub-id><pub-id pub-id-type="pmid">32741372</pub-id><pub-id pub-id-type="pmcid">PMC7395940</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chukwudozie</surname><given-names>OS</given-names></name><name name-style="western"><surname>Gray</surname><given-names>CM</given-names></name><name name-style="western"><surname>Fagbayi</surname><given-names>TA</given-names></name><name name-style="western"><surname>Chukwuanukwu</surname><given-names>RC</given-names></name><name name-style="western"><surname>Oyebanji</surname><given-names>VO</given-names></name><name name-style="western"><surname>Bankole</surname><given-names>TT</given-names></name><etal/></person-group>. <article-title>Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein</article-title>. <source>PLoS One</source>. (<year>2021</year>) <volume>16</volume>:<elocation-id>e0248061</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0248061</pub-id><pub-id pub-id-type="pmid">33730022</pub-id><pub-id pub-id-type="pmcid">PMC7968690</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basmenj</surname><given-names>ER</given-names></name><name name-style="western"><surname>Pajhouh</surname><given-names>SR</given-names></name><name name-style="western"><surname>Ebrahimi Fallah</surname><given-names>A</given-names></name><name name-style="western"><surname>Naijian</surname><given-names>R</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>E</given-names></name><name name-style="western"><surname>Atighy</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Computational epitope-based vaccine design with bioinformatics approach; a review</article-title>. <source>Heliyon</source>. (<year>2025</year>) <volume>11</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.heliyon.2025.e41714</pub-id><pub-id pub-id-type="pmcid">PMC11761309</pub-id><pub-id pub-id-type="pmid">39866399</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olawade</surname><given-names>DB</given-names></name><name name-style="western"><surname>Teke</surname><given-names>J</given-names></name><name name-style="western"><surname>Fapohunda</surname><given-names>O</given-names></name><name name-style="western"><surname>Weerasinghe</surname><given-names>K</given-names></name><name name-style="western"><surname>Usman</surname><given-names>SO</given-names></name><name name-style="western"><surname>Ige</surname><given-names>AO</given-names></name><etal/></person-group>. <article-title>Leveraging artificial intelligence in vaccine development: A narrative review</article-title>. <source>J Microbiological Methods</source>. (<year>2024</year>) <volume>224</volume>:<fpage>106998</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.mimet.2024.106998</pub-id><pub-id pub-id-type="pmid">39019262</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somogyi</surname><given-names>E</given-names></name><name name-style="western"><surname>Csiszovszki</surname><given-names>Z</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>L</given-names></name><name name-style="western"><surname>L&#337;rincz</surname><given-names>O</given-names></name><name name-style="western"><surname>T&#243;th</surname><given-names>J</given-names></name><name name-style="western"><surname>Pattijn</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A peptide vaccine candidate tailored to individuals&#8217; Genetics mimics the multi-targeted T cell immunity of COVID-19 convalescent subjects</article-title>. <source>Front Genet</source>. (<year>2021</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fgene.2021.684152</pub-id><pub-id pub-id-type="pmcid">PMC8261158</pub-id><pub-id pub-id-type="pmid">34249101</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kheirvari</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name></person-group>. <article-title>Virus-like particle vaccines and platforms for vaccine development</article-title>. <source>Viruses</source>. (<year>2023</year>) <volume>15</volume>:<page-range>1109&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v15051109</pub-id><pub-id pub-id-type="pmcid">PMC10223759</pub-id><pub-id pub-id-type="pmid">37243195</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caucheteux</surname><given-names>SM</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>JP</given-names></name><name name-style="western"><surname>Ivory</surname><given-names>MO</given-names></name><name name-style="western"><surname>Hirosue</surname><given-names>S</given-names></name><name name-style="western"><surname>Hakobyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Dolton</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1</article-title>. <source>J Invest Dermatol</source>. (<year>2016</year>) <volume>136</volume>:<page-range>1172&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jid.2016.01.033</pub-id><pub-id pub-id-type="pmid">26896775</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pizzolato-Cezar</surname><given-names>LR</given-names></name><name name-style="western"><surname>Okuda-Shinagawa</surname><given-names>NM</given-names></name><name name-style="western"><surname>Machini</surname><given-names>MT</given-names></name></person-group>. <article-title>Combinatory therapy antimicrobial peptide-antibiotic to minimize the ongoing rise of resistance</article-title>. <source>Front Microbiol</source>. (<year>2019</year>) <volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2019.01703</pub-id><pub-id pub-id-type="pmcid">PMC6695574</pub-id><pub-id pub-id-type="pmid">31447797</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3K&#947; inhibitor can enhance immunogenicity and eradicate tumors</article-title>. <source>J ImmunoTherapy Cancer</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>e003564</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2021-003564</pub-id><pub-id pub-id-type="pmcid">PMC8883272</pub-id><pub-id pub-id-type="pmid">35217574</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotraiah</surname><given-names>V</given-names></name><name name-style="western"><surname>Phares</surname><given-names>TW</given-names></name><name name-style="western"><surname>Browne</surname><given-names>CD</given-names></name><name name-style="western"><surname>Pannucci</surname><given-names>J</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>M</given-names></name><name name-style="western"><surname>Noe</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Novel peptide-based PD1 immunomodulators demonstrate efficacy in infectious disease vaccines and therapeutics</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00264</pub-id><pub-id pub-id-type="pmcid">PMC7068811</pub-id><pub-id pub-id-type="pmid">32210956</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>